[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 126681
1. Asghar H, Rahko PS: Quality of heart failure management: a comparison of care between a comprehensive heart failure program and a general cardiology practice. Congest Heart Fail; 2010 Mar-Apr;16(2):65-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of heart failure management: a comparison of care between a comprehensive heart failure program and a general cardiology practice.
  • This study evaluates adherence to guidelines by heart failure clinicians (HFCs) vs general cardiologists (GCs) for use of implantable cardioverter-defibrillators (ICDs), biventricular pacing devices (cardiac resynchronization therapy; CRT), and use of medications for heart failure (HF).
  • The authors reviewed 563 patients with HF and an ejection fraction <or=35% for adherence to the 2005 American College of Cardiology/American Heart Association HF guidelines for the use of ICDs, CRT, and medications.
  • [MeSH-major] Cardiology / statistics & numerical data. Guideline Adherence. Heart Failure / therapy. Practice Patterns, Physicians' / statistics & numerical data. Quality of Health Care / statistics & numerical data
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Aged. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Cardiac Pacing, Artificial. Coronary Care Units. Defibrillators, Implantable. Diuretics / therapeutic use. Female. Health Status Indicators. Humans. Male. Middle Aged. Retrospective Studies. Severity of Illness Index. Stroke Volume. Ventricular Function, Left. Wisconsin

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20412471.001).
  • [ISSN] 1751-7133
  • [Journal-full-title] Congestive heart failure (Greenwich, Conn.)
  • [ISO-abbreviation] Congest Heart Fail
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Diuretics
  •  go-up   go-down


2. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC: Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol; 2009 Jan 13;53(2):184-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.
  • OBJECTIVES: We sought to examine associations between initiation of beta-blocker therapy and outcomes among elderly patients hospitalized for heart failure.
  • BACKGROUND: Beta-blockers are guideline-recommended therapy for heart failure, but their clinical effectiveness is not well understood, especially in elderly patients.
  • METHODS: We merged Medicare claims data with OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) records to examine long-term outcomes of eligible patients newly initiated on beta-blocker therapy.
  • Among 7,154 patients hospitalized with heart failure and eligible for beta-blockers, 3,421 (49%) were newly initiated on beta-blocker therapy.
  • CONCLUSIONS: In elderly patients hospitalized with heart failure and LVSD, incident beta-blocker use was clinically effective and independently associated with lower risks of death and rehospitalization.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2004 Oct 19;44(8):1587-92 [15489090.001]
  • [Cites] Am Heart J. 2004 Jul;148(1):43-51 [15215791.001]
  • [Cites] Arch Intern Med. 1997 Jan 13;157(1):99-104 [8996046.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):9-13 [10023943.001]
  • [Cites] Lancet. 1999 Jun 12;353(9169):2001-7 [10376614.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):841-53 [15386709.001]
  • [Cites] Eur Heart J. 2005 Feb;26(3):215-25 [15642700.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1240-7 [16160132.001]
  • [Cites] Circulation. 2005 Sep 20;112(12):e154-235 [16160202.001]
  • [Cites] JAMA. 2006 Nov 8;296(18):2217-26 [17090768.001]
  • [Cites] Am Heart J. 2007 Jan;153(1):82.e1-11 [17174643.001]
  • [Cites] JAMA. 2007 Jan 3;297(1):61-70 [17200476.001]
  • [Cites] Am Heart J. 2007 Apr;153(4):515-22 [17383287.001]
  • [Cites] Arch Intern Med. 2007 Jul 23;167(14):1493-502 [17646603.001]
  • [Cites] Am J Cardiol. 2007 Aug 15;100(4):690-6 [17697830.001]
  • [Cites] J Card Fail. 2007 Nov;13(9):722-31 [17996820.001]
  • [Cites] Circulation. 2008 Jan 29;117(4):e25-146 [18086926.001]
  • [Cites] N Engl J Med. 2001 May 31;344(22):1651-8 [11386263.001]
  • [Cites] Circ Heart Fail. 2008 Jul;1(2):91-7 [19300532.001]
  • [Cites] N Engl J Med. 1996 May 23;334(21):1349-55 [8614419.001]
  • [Cites] Biometrics. 2001 Dec;57(4):1207-18 [11764262.001]
  • [Cites] Arch Intern Med. 2002 Aug 12-26;162(15):1682-8 [12153370.001]
  • [Cites] Am J Med. 2004 May 1;116(9):581-9 [15093753.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):45-9 [15158046.001]
  • [CommentIn] J Am Coll Cardiol. 2009 Dec 1;54(23):2202 [19942096.001]
  • (PMID = 19130987.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL066461-05; United States / NIA NIH HHS / AG / 1R01 AG026038-01A1; United States / NIA NIH HHS / AG / AG026038-01A1; United States / NHLBI NIH HHS / HL / U01 HL066461; United States / NIA NIH HHS / AG / R01 AG026038-01A1; United States / NHLBI NIH HHS / HL / U01 HL066461-05; United States / NIA NIH HHS / AG / R01 AG026038; United States / NHLBI NIH HHS / HL / 5U01 HL66461-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists
  • [Other-IDs] NLM/ NIHMS210933; NLM/ PMC3513266
  •  go-up   go-down


3. Deng W, Ding YL, Fan XM, Yu L, Zhu FF, Ding H: [Management of heart failure and timing of delivery in pregnancy]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct;30(5):583-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of heart failure and timing of delivery in pregnancy].
  • OBJECTIVE: To explore the management of heart failure, the timing of delivery in pregnancy, and the influence on pregnant prognosis.
  • METHODS: We retrospectively analyzed the incidence of heart failure, treatment results, pattern of termination, and time of termination in 356 cases of pregnancy with heart disease.
  • RESULTS: One hundred and thirty-six (38.20%) cases were diagnosed as heart failure and 76 (55.88%) were moderate or severe heart failure.
  • Heart failure tends to occur more easily in rheumatic heart diseases than in congenital heart diseases.
  • Heart failure occurred more frequently in pregnancy with rheumatic heart diseases without the heart operation before pregnancy than that of pregnancy with congenital heart diseases.
  • The occurence of the moderate and severe heart failure in pregnancy decreased in rheumatic heart diseases with surgical therapies compared with those without surgical therapies (P <0.05).
  • Compared with pregnancy with heart failure controlled inadequately, pregnancy with effectively controlled heart failure had better tolerance during delivery and through the pregnancy, and puerperium.
  • CONCLUSION: Congenital heart diseases and rheumatic heart diseases are the chief causes of heart failure during the gestation.
  • Therapy before pregnancy, especially surgery to the rheumatic heart diseases, may improve the cardiac function during pregnancy.
  • Monitoring heart function and selecting the proper timing to terminate pregnancy after controlling the heart failure in late pregnant period will be helpful to improve the prognosis of pregnant and perineonate.
  • [MeSH-major] Delivery, Obstetric. Heart Failure / therapy. Pregnancy Complications, Cardiovascular / therapy. Rheumatic Heart Disease / complications
  • [MeSH-minor] Adult. Female. Heart Defects, Congenital / complications. Humans. Pregnancy. Pregnancy Outcome. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Childbirth.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323315.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Saadi HF, Kazzam E, Ghurbana BA, Nicholls MG: Hypothesis: Correction of low vitamin D status among Arab women will prevent heart failure and improve cardiac function in established heart failure. Eur J Heart Fail; 2006 Nov;8(7):694-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypothesis: Correction of low vitamin D status among Arab women will prevent heart failure and improve cardiac function in established heart failure.
  • Apart from its adverse effects on bone in women and their offspring, vitamin D deficiency has the potential to cause or exacerbate heart failure through a number of mechanisms including activation of the renin-angiotensin system and increased arterial pressure.
  • In particular, we suggest that prevention and correction of vitamin D deficiency will reduce the incidence of heart failure and, for Arab women with established heart failure and vitamin D deficiency, improve cardiac function.
  • [MeSH-major] Arabs / statistics & numerical data. Heart Failure / etiology. Heart Failure / prevention & control. Vitamin D / administration & dosage. Vitamin D Deficiency / complications. Vitamin D Deficiency / epidemiology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828339.001).
  • [ISSN] 1388-9842
  • [Journal-full-title] European journal of heart failure
  • [ISO-abbreviation] Eur. J. Heart Fail.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  •  go-up   go-down


5. Ripley TL: Valsartan in chronic heart failure. Ann Pharmacother; 2005 Mar;39(3):460-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valsartan in chronic heart failure.
  • OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and determine its need for formulary inclusion.
  • DATA SOURCES: OVID and PubMed databases were searched (1983-June 2004) using the key words angiotensin-receptor blocker, heart failure, valsartan, Diovan, and angiotensin-converting enzyme inhibitor.
  • Prospective, randomized clinical trials investigating the use of valsartan and other angiotensin-receptor blockers (ARBs) in chronic heart failure were evaluated.
  • DATA SYNTHESIS: Valsartan, a selective antagonist for angiotensin receptor subtype 1, is the first ARB to be approved for use in chronic heart failure.
  • Clinical trial data support valsartan as an alternative to angiotensin-converting enzyme (ACE) inhibitors in ACE inhibitor-intolerant patients with chronic heart failure.
  • Candesartan's data support its use in heart failure; however, losartan's data have been less consistent.
  • CONCLUSIONS: Valsartan is a safe and effective alternative for heart failure patients intolerant of ACE inhibitors.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / therapeutic use. Heart Failure / drug therapy. Tetrazoles / therapeutic use. Valine / analogs & derivatives. Valine / therapeutic use

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALSARTAN .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15687480.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Tetrazoles; 80M03YXJ7I / Valsartan; HG18B9YRS7 / Valine
  • [Number-of-references] 50
  •  go-up   go-down


6. Boonprasert P, Lailerd N, Chattipakorn N: Urocortins in heart failure and ischemic heart disease. Int J Cardiol; 2008 Jul 21;127(3):307-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urocortins in heart failure and ischemic heart disease.
  • In the heart, urocortins have been demonstrated to produce cardioprotective effects during ischemia and reperfusion injury.
  • Urocortins have also exerted effects on hemodynamic, endocrine and renal parameters in experimental animal heart failure models.
  • In humans, plasma urocortin levels have been shown to significantly increase in systolic heart failure patients.
  • This growing evidence suggests that urocortins may have a prognostic value as well as being a potential therapeutic treatment for heart failure and myocardial infarction patients.
  • In this review article, the role of urocortins in the heart has been summarized.
  • Their possible beneficial roles in heart failure and myocardial infarction have been discussed, based on relevant published articles from both basic and clinical studies available to date.
  • [MeSH-major] Heart Failure / blood. Myocardial Ischemia / blood. Urocortins / blood

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180061.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Urocortins
  • [Number-of-references] 70
  •  go-up   go-down


7. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF: C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease. J Intern Med; 2006 Oct;260(4):377-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease.
  • OBJECTIVES: Increased C-reactive protein (CRP) and reduced heart rate variability (HRV) both indicate poor prognosis.
  • SUBJECTS: A total of 638 middle-aged and elderly subjects with no apparent heart disease from community.
  • CONCLUSIONS: The combination of CRP and HRV or heart rate (HR) predicts death and myocardial infarction with synergism, indicating interaction between inflammatory and autonomic systems with a prognostic significance.
  • [MeSH-major] C-Reactive Protein / analysis. Heart Rate / physiology

  • Genetic Alliance. consumer health - Heart Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961675.001).
  • [ISSN] 0954-6820
  • [Journal-full-title] Journal of internal medicine
  • [ISO-abbreviation] J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


8. Suzuki H, Watanabe S, Hamaguchi T, Mine H, Terui T, Kanazawa M, Oohisa N, Maruyama M, Yambe T, Itoh M, Fukudo S: Brain activation associated with changes in heart rate, heart rate variability, and plasma catecholamines during rectal distention. Psychosom Med; 2009 Jul;71(6):619-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain activation associated with changes in heart rate, heart rate variability, and plasma catecholamines during rectal distention.
  • RESULTS: Rectal distention with 40 mm Hg induced a significant increase in heart rate, low frequency (LF)/high frequency (HF) ratio of heart rate variability, and plasma adrenaline.
  • Activated brain areas that were associated with increased heart rate during rectal distention were the right insula, right operculum, right dorsolateral prefrontal cortex, putamen, thalamus, periaqueductal gray, and cerebellum (p < .001, uncorrected), whereas those that were associated with an increased LF/HF ratio were the bilateral insula, putamen, thalamus, midbrain, pons, and cerebellum (p < .001, uncorrected).
  • [MeSH-major] Arousal / physiology. Autonomic Nervous System / physiology. Brain / physiology. Catecholamines / blood. Heart Rate / physiology. Rectum / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561165.001).
  • [ISSN] 1534-7796
  • [Journal-full-title] Psychosomatic medicine
  • [ISO-abbreviation] Psychosom Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; YKH834O4BH / Epinephrine
  •  go-up   go-down


9. Wei J, Chang CY, Chuang YC, Chen HL: Updates in heart transplantation. Transplant Proc; 2008 Oct;40(8):2594-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updates in heart transplantation.
  • Heart transplantation (HTx) has been a successful therapy for patients with end-stage heart failure.
  • In June 1996, we performed combined heart and kidney transplantation after bridging for 14 days with an indigenous total artificial heart (TAH).
  • A 14-year-old boy had full recovery of heart function after receiving a donor heart after 13 hours of ischemia in 2003.
  • [MeSH-major] Heart Transplantation / trends
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Cardiopulmonary Resuscitation. Child. Child, Preschool. Coronary Disease / epidemiology. Extracorporeal Membrane Oxygenation. Female. Heart, Artificial. Humans. Kidney Transplantation. Male. Middle Aged. Postoperative Complications / classification. Retrospective Studies. Taiwan

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929810.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators: Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation; 2007 Sep 25;116(13):1482-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
  • BACKGROUND: Patients with chronic heart failure (HF) are at increased risk of both fatal and nonfatal major adverse cardiovascular events.
  • We used data from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) trials to assess the influence of nonfatal hospitalizations for HF on subsequent mortality rates in a broad spectrum of HF patients.
  • METHODS AND RESULTS: In the present study, 7599 patients with New York Heart Association class II to IV HF and reduced or preserved left ventricular ejection fraction were randomized to placebo or candesartan.
  • Moreover, risk of death was highest within a month of discharge and then declined progressively over time, particularly for death resulting from HF progression and for sudden cardiac death.
  • [MeSH-major] Heart Failure / mortality. Hospitalization / statistics & numerical data
  • [MeSH-minor] Aftercare. Aged. Aged, 80 and over. Angiotensin II Type 1 Receptor Blockers / therapeutic use. Benzimidazoles / therapeutic use. Death, Sudden, Cardiac / epidemiology. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Proportional Hazards Models. Randomized Controlled Trials as Topic / statistics & numerical data. Survival Analysis. Tetrazoles / therapeutic use


11. Chatterjee K: Hyponatremia in heart failure. J Intensive Care Med; 2009 Nov-Dec;24(6):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyponatremia in heart failure.
  • Hyponatremia is one of the newer and emerging risk factors for an adverse prognosis in chronic heart failure.
  • It may reflect worsening heart failure and the deleterious effects of activation of neurohormones.
  • The mechanism of hyponatremia in heart failure also remains unclear.
  • The treatment of significant hyponatremia in heart failure is difficult.
  • However, long-term beneficial effects of such treatments in chronic heart failure have not been documented.
  • [MeSH-major] Antidiuretic Hormone Receptor Antagonists. Heart Failure / physiopathology. Hyponatremia / drug therapy. Hyponatremia / physiopathology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Tolvaptan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850560.001).
  • [ISSN] 1525-1489
  • [Journal-full-title] Journal of intensive care medicine
  • [ISO-abbreviation] J Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiuretic Hormone Receptor Antagonists; 0 / Benzazepines; 0NJ98Y462X / conivaptan; 21G72T1950 / tolvaptan
  • [Number-of-references] 24
  •  go-up   go-down


12. Li H, Xie SY, Lu WX: [Relationship of Chinese medicine syndrome pattern with heart function and brain natriuretic peptide in patients with heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Sep;30(9):919-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship of Chinese medicine syndrome pattern with heart function and brain natriuretic peptide in patients with heart failure].
  • OBJECTIVE: To observe the relationship of Chinese medicine (CM) syndrome pattern with heart function detected by ultrasonic cardiography and brain natriuretic peptide (BNP) level in patients with heart failure (HF).
  • CONCLUSION: LVEF and BNP can reflect the severity of heart failure, and they could be taken as the beneficial objective and quantitative indices for syndrome pattern differentiation.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21179728.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


13. Blum A: Heart failure--new insights. Isr Med Assoc J; 2009 Feb;11(2):105-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart failure--new insights.
  • Ten years ago we published a review updating current knowledge on heart failure.
  • We summarized that heart failure is a neuro-humoral and inflammatory syndrome, and that proinflammatory cytokines are involved in cardiac depression and in the complex syndrome of heart failure.
  • We suggested that understanding the role of these cytokines may enable us to reverse cardiac depression and heart failure.
  • This review will focus on the up-to-date mechanistic aspects of heart failure, including clinical trials that have contributed to our better understanding of this entity.
  • [MeSH-major] Heart Failure / etiology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432040.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Endothelins; 0 / Interleukin-6
  • [Number-of-references] 39
  •  go-up   go-down


14. Fraser A, May M, Lowe G, Rumley A, Smith GD, Ebrahim S, Lawlor DA: Interleukin-6 and incident coronary heart disease: results from the British Women's Heart and Health Study. Atherosclerosis; 2009 Feb;202(2):567-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 and incident coronary heart disease: results from the British Women's Heart and Health Study.
  • The purpose of this study was to determine whether IL-6 is associated with incident coronary heart disease (CHD) events independently of established risk factors and to examine its predictive ability for future CHD events.
  • METHODS: Data from the British Women's Heart and Health Study, a prospective cohort of randomly sampled British women 60-79 years old at baseline was used.
  • Three thousand five hundred and eighty-one women had no evidence of coronary heart disease at baseline and were followed up for a median of 4.6 years.

  • Genetic Alliance. consumer health - Heart Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556001.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600705; United Kingdom / British Heart Foundation / / ; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6
  •  go-up   go-down


15. Pangonyte D, Stalioraityte E, Kazlauskaite D, Ziuraitiene R, Stanioniene Z, Kerpauskiene S: [Changes of heart geometry in patients with ischemic heart disease]. Medicina (Kaunas); 2008;44(1):8-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes of heart geometry in patients with ischemic heart disease].
  • OBJECTIVE: The aim of the study was to determine ventricular and atrial cardiometric parameters at preinfarction and postinfarction stage of ischemic heart disease.
  • OBJECT AND METHODS: Cardiometric parameters (mass, endocardial surface area, the tracts of flow and outflow, etc.) of 132 men (mean age of 49.7+/-8.9 years) who had died suddenly during prehospital period (within 6 hours) after the first or repeated acute event of "pure" ischemic heart disease were investigated.
  • These patients had no other, except ischemia, factors predisposing myocardial hypertrophy as well as clinical symptoms of heart failure.
  • The decedents were divided into preinfarction (71 men) and postinfarction ischemic heart disease (61 men) groups.
  • RESULTS: At preinfarction stage of ischemic heart disease, mass and endocardial surface area of all parts of the heart were increased, the tracts of flow and outflow--longer.
  • CONCLUSIONS: Eccentric type of left ventricular hypertrophy (proportional increase of mass and endocardial surface area) and concentric type of right ventricular and right and left atrial hypertrophy (the part of myocardium mass per unit of endocardial area is greater) were determined at preinfarction stage of ischemic heart disease.
  • At postinfarction stage, at least as far as evidence of heart failure is not overt, only the corresponding left ventricular and atrial hypertrophy progresses.
  • [MeSH-major] Death, Sudden, Cardiac / pathology. Hypertrophy, Left Ventricular / pathology. Myocardial Infarction / pathology. Myocardial Ischemia / pathology. Myocardium / pathology

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277083.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


16. Kumar D, Carvalho P, Antunes M, Henriques J, Sá e Melo A, Habetha J: Heart murmur recognition and segmentation by complexity signatures. Conf Proc IEEE Eng Med Biol Soc; 2008;2008:2128-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart murmur recognition and segmentation by complexity signatures.
  • Heart sound analysis has been a topic of investigation for several years.
  • Since heart sounds directly encode the mechanical activity of the heart, they enable the assessment and follow-up of several types of heart disorders in pre-symptomatic states.
  • Murmurs are the most common abnormality signature in many heart disorders.
  • This paper introduces an algorithm for heart murmur identification.
  • In the presence of murmurs, heart sounds exhibit chaotic behavior.
  • In order to segment murmurs from other heart sound components, the signal is transformed into a phase space that is later reconstructed using the embedded matrix.
  • The method has been tested with a database of heart sounds that include diverse heart lesions and heart murmurs.
  • [MeSH-major] Heart Murmurs / diagnosis. Models, Cardiovascular. Signal Processing, Computer-Assisted
  • [MeSH-minor] Algorithms. Heart Sounds. Humans. Nonlinear Dynamics. Phonocardiography / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19163117.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Karsdorp PA, Kindt M, Rietveld S, Everaerd W, Mulder BJ: Stress-induced heart symptoms and perceptual biases in patients with congenital heart disease. Int J Cardiol; 2007 Jan 18;114(3):352-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stress-induced heart symptoms and perceptual biases in patients with congenital heart disease.
  • BACKGROUND: The aim of the present study is to clarify whether biased symptom perception towards heart symptoms may explain a reduced quality of life in patients with congenital heart disease (ConHD).
  • The present study tested the hypothesis that the combination of ConHD and high trait anxiety increases the perception of heart symptoms during acute stress.
  • Participant's heart and non-heart symptoms were measured after stress and after relaxation.
  • Heart rate, blood pressure, respiratory rate, and arterial partial pressure of CO2 were monitored continuously.
  • RESULTS: In line with the prediction, a combination of high trait anxiety and ConHD resulted in an increased perception of specifically heart symptoms during stress.
  • Moreover, the increased perception of heart symptoms could not be explained by acute heart dysfunction.
  • CONCLUSIONS: Heart dysfunction is not the only cause of an increased perception of heart symptoms.
  • A history of disease experience in combination with high trait anxiety may increase the perception of heart symptoms during stress and may eventually result in an increased risk of developing a reduced quality of life.
  • [MeSH-major] Heart Defects, Congenital / psychology. Perception. Quality of Life. Stress, Psychological / psychology


18. Wang X, Ji Q, Mei Y, Yu H, Feng J, Cai J, Sun Y, Zhu C, Li D: Venous hemangioma in the right atrium possibly related to radiofrequency catheter ablation. Circ J; 2008 Oct;72(10):1712-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Venous hemangioma is a rare, benign cardiac tumor, usually in young or adult males.
  • [MeSH-major] Catheter Ablation / adverse effects. Heart Diseases / ultrasonography. Hemangioma / ultrasonography. Tachycardia, Supraventricular / surgery


19. Brazdzionyte J, Macas A, Mickeviciene A: [Acute heart failure]. Medicina (Kaunas); 2006;42(8):682-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute heart failure].
  • There are still many discussions among physicians how heart failure should be defined.
  • A new approach of acute heart failure classification suggested by European Society of Cardiology is presented in the article.
  • Diagnostic strategy of acute heart failure as well as recommendations for prehospital and inpatient treatment of its forms (pulmonary edema and cardiogenic shock) are presented in the article.
  • Application of new medications, recently introduced to the clinical practice for treatment of acute heart failure, is discussed.
  • [MeSH-major] Heart Failure
  • [MeSH-minor] Acute Disease. Angiotensin-Converting Enzyme Inhibitors / administration & dosage. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Cardiotonic Agents / administration & dosage. Cardiotonic Agents / therapeutic use. Diuretics / administration & dosage. Diuretics / therapeutic use. Echocardiography. Electrocardiography. Hemodynamics. Humans. Myocardial Revascularization. Nitroglycerin / administration & dosage. Nitroglycerin / therapeutic use. Oxygen Inhalation Therapy. Pulmonary Edema / diagnosis. Pulmonary Edema / drug therapy. Pulmonary Edema / therapy. Shock, Cardiogenic / diagnosis. Shock, Cardiogenic / drug therapy. Shock, Cardiogenic / surgery. Shock, Cardiogenic / therapy. Vasodilator Agents / administration & dosage. Vasodilator Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16963836.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Cardiotonic Agents; 0 / Diuretics; 0 / Vasodilator Agents; G59M7S0WS3 / Nitroglycerin
  • [Number-of-references] 19
  •  go-up   go-down


20. Kyo S, Nishimura T, Gojo S, Ono M: [Heart transplantation]. Nihon Rinsho; 2010 Dec;68(12):2271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Heart transplantation].
  • Although the clinical outcome of heart transplantation in Japan is excellent in the past 11 years after establishment of the Organ Transplant Law, the total number of heart transplant is extremely limited in Japan, only 69 cases.
  • The Law was revised and enforced in July 17, 2010, and pediatric heart transplantation is authorized in Japan from the legal point of view under the revised law.
  • We expect the number of the heart transplantation will be increased up to 30 to 50 cases per year, and social conditions are required also to be revised according to the revision of the Organ Transplant Law.
  • [MeSH-major] Heart Transplantation / statistics & numerical data

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174691.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Lee DS, Vasan RS: Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol; 2005 May;20(3):201-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel markers for heart failure diagnosis and prognosis.
  • PURPOSE OF REVIEW: This paper reviews recent advances in heart failure biomarkers for identification of disease precursors, subclinical disease, and onset or progression of overt disease.
  • RECENT FINDINGS: Heart failure biomarkers can be categorized empirically as neurohormonal mediators, markers of myocyte injury and remodeling, and indicators of systemic inflammation.
  • Strong evidence exists for use of brain natriuretic peptide in the diagnosis of acute heart failure and for improved clinical outcomes with a brain natriuretic peptide-guided approach to heart failure care.
  • The use of brain natriuretic peptide as a screening tool for asymptomatic left ventricular systolic dysfunction, or to distinguish systolic from diastolic heart failure, is not supported by current data.
  • Markers of myocyte injury, including troponins, heart-type fatty acid binding protein, and myosin light chain-1, may further improve heart failure prognostication in conjunction with plasma brain natriuretic peptide.
  • Biomarkers of matrix remodeling and inflammation have emerged as potential preclinical indicators to identify individuals at risk of developing clinical heart failure.
  • SUMMARY: The spectrum of heart failure biomarkers and their potential clinical applications continues to grow.
  • Ongoing research on multimarker strategies will likely identify biomarker combinations that are optimal at various stages during the evolution of heart failure, ranging from their use for screening, diagnosis, determining prognosis, and guiding management.
  • [MeSH-major] Heart Failure / diagnosis. Natriuretic Peptide, Brain / blood. Troponin / blood

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861008.001).
  • [ISSN] 0268-4705
  • [Journal-full-title] Current opinion in cardiology
  • [ISO-abbreviation] Curr. Opin. Cardiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / 1R01HL67288; United States / NHLBI NIH HHS / HL / 2K24HL04334; United States / NHLBI NIH HHS / HC / N01-HC-25195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carrier Proteins; 0 / Fatty Acid-Binding Proteins; 0 / Myosin Light Chains; 0 / Troponin; 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 138
  •  go-up   go-down


22. Jankowska EA, Ponikowski P, European Society of Cardiology: Heart failure classifications - guidelines. Contrib Nephrol; 2010;164:11-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart failure classifications - guidelines.
  • The clinical syndrome of heart failure is hugely heterogeneous.
  • Classifications are based on the time course of the clinical presentation of heart failure, severity of symptoms and signs of heart failure, structural changes within the heart, predominant etiology and comorbidities.
  • [MeSH-major] Cardiology. Heart Failure / classification. Heart Failure / diagnosis. Practice Guidelines as Topic. Water-Electrolyte Imbalance

  • MedlinePlus Health Information. consumer health - Fluid and Electrolyte Balance.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 64C S. Karger AG, Basel.
  • (PMID = 20427989.001).
  • [ISSN] 1662-2782
  • [Journal-full-title] Contributions to nephrology
  • [ISO-abbreviation] Contrib Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Couvreur N, Tissier R, Pons S, Chetboul V, Gouni V, Bruneval P, Mandet C, Pouchelon JL, Berdeaux A, Ghaleh B: Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression. Eur Heart J; 2010 Jun;31(12):1529-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression.
  • AIMS: To investigate the adaptations of left ventricular function and calcium handling to chronic heart rate reduction with ivabradine in the reperfused heart.
  • Ivabradine reduced heart rate by about 20% and improved both ejection fraction (+35%) and systolic displacement (+26%) after 3 weeks of treatment.
  • CONCLUSION: Chronic heart rate reduction protects the myocardium against ventricular dysfunction induced by myocardial ischaemia followed by 3 weeks of reperfusion.
  • Beyond pure heart rate reduction, ivabradine improves global and regional systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term adaptation in calcium handling, as supported by the increase in FKBP12/12.6 expression.
  • [MeSH-major] Anti-Arrhythmia Agents / pharmacology. Benzazepines / pharmacology. Heart Rate / drug effects. Tacrolimus Binding Protein 1A / metabolism

  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circ Res. 2002 Aug 23;91(4):323-30 [12193465.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Feb;284(2):H676-82 [12399255.001]
  • [Cites] Circulation. 2004 Apr 6;109(13):1674-9 [14981003.001]
  • [Cites] J Physiol. 2004 May 1;556(Pt 3):919-34 [14966299.001]
  • [Cites] Eur Heart J. 2004 Apr;25(7):579-86 [15120055.001]
  • [Cites] Circulation. 2004 Jun 29;109(25):3208-14 [15197150.001]
  • [Cites] Circulation. 1987 Mar;75(3):661-9 [3815774.001]
  • [Cites] Br J Pharmacol. 1994 May;112(1):37-42 [8032660.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Nov;275(2):659-66 [7473152.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3456-61 [16481613.001]
  • [Cites] J Mol Cell Cardiol. 2007 Jan;42(1):79-87 [17141266.001]
  • [Cites] Cardiovasc Res. 2007 Feb 1;73(3):560-7 [17188666.001]
  • [Cites] Br J Pharmacol. 2007 Feb;150(3):335-41 [17179940.001]
  • [Cites] Eur Heart J. 2007 Apr;28(7):872-9 [17376788.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H590-8 [17384136.001]
  • [Cites] Br J Pharmacol. 2008 Apr;153(8):1589-601 [18223669.001]
  • [Cites] Cardiovasc Res. 2008 Jun 1;78(3):466-75 [18252758.001]
  • [Cites] Cardiovasc Res. 2008 Jul 1;79(1):42-51 [18310678.001]
  • [Cites] Eur Heart J. 2008 Sep;29(18):2265-75 [18621770.001]
  • [Cites] Br J Pharmacol. 2008 Dec;155(7):970-1 [18846042.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H435-41 [19074674.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H322-30 [19411283.001]
  • [Cites] Cell. 2000 May 12;101(4):365-76 [10830164.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H38-43 [12063272.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Feb;282(2):H672-9 [11788417.001]
  • [Cites] Br J Pharmacol. 2000 Jun;130(4):767-76 [10864882.001]
  • [Cites] Circ Res. 2001 Jun 8;88(11):1151-8 [11397781.001]
  • [Cites] Circ Res. 2001 Feb 2;88(2):188-94 [11157671.001]
  • [Cites] J Mol Cell Cardiol. 2001 Mar;33(3):441-8 [11181013.001]
  • (PMID = 20028694.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Benzazepines; 0 / Calcium-Binding Proteins; 3H48L0LPZQ / ivabradine; EC 5.2.1.- / Tacrolimus Binding Protein 1A
  • [Other-IDs] NLM/ HALMS500900; NLM/ PMC3064678
  •  go-up   go-down


24. Zamaklar-Trifunović D, Seferović PM, Zivković M, Jelić V, Vukomanović G, Petrović M, Milić N, Ristić AD, Simeunović D: [Influence of heart failure severity on heart rate variability]. Srp Arh Celok Lek; 2005 Nov-Dec;133(11-12):484-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of heart failure severity on heart rate variability].
  • INTRODUCTION: Autonomic regulation of cardiovascular functions in congestive heart failure is characterised by enhanced sympathetic and diminished parasympathetic activity.
  • The long term predominance of sympathetic tone is a significant factor in arrhythmogenesis, sudden cardiac death, and progressive pump failure.
  • Heart rate variability (HRV) is a noninvasive method for estimating the sympatho vagal balance in cardiovascular control.
  • AIM: The aim of this study was to analyse the influence of heart failure severity on HRV.
  • RESULTS: All spectral componentswere statistically, significantly lower in patients with heart failure in comparison to healthy controls (VLF: 159.89 +/- 147.02 vs. 285.50 +/- 202.77 ms2; p = 0.023, LF: 161.48 +/- 204.01 vs. 474.57 +/- 362.93 ms2; p < 0.001, HF: 88.58 +/- 102.47 vs. 362.71+/- 318.28 ms2; p < 0.001), as well as total power (Tot Power: 723.39 +/- 644.52 vs. 1807.29 +/- 1204.74 ms2; p < 0.001).
  • A significant, negative correlation between HRV parameters and NYHA class was detected in heart failure patients (VLF: r = -0.391; p = 0.002, LF: r = -0.401; p = 0.001, and Tot Power r = -0.372; p = 0.003).
  • CONCLUSION: Significant HRV reduction is a precursor to incipient heart failure (NYHA I).
  • In heart failure progression, total power as well as the power of all spectral components is progressively reduced.
  • LF and Tot Power are the most prominent parameters for discriminating between the different stages of heart failure.
  • These results could promote HRV as an important decision-making tool in heart failure treatment as well as in monitoring the results of that treatment.
  • [MeSH-major] Heart Failure / physiopathology. Heart Rate

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758848.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


25. Shaddy RE, Webb G: Applying heart failure guidelines to adult congenital heart disease patients. Expert Rev Cardiovasc Ther; 2008 Feb;6(2):165-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Applying heart failure guidelines to adult congenital heart disease patients.
  • There is a growing population of adult patients with congenital heart defects in the developed world.
  • Some have heart failure.
  • As a group, they show neurohormonal activation similar to that seen in an adult heart failure population with acquired heart disease.
  • Currently, the patients at greatest risk of heart failure are those without a systemic left ventricle, such as Mustard and Senning repairs of transposition of the great arteries (TGA), congenitally corrected TGA, and patients who have had a Fontan procedure.
  • For those patients with systemic left ventricles, it would seem reasonable to use the heart failure guidelines developed for patients with acquired heart disease.
  • [MeSH-major] Heart Defects, Congenital / therapy. Heart Failure / therapy. Practice Guidelines as Topic
  • [MeSH-minor] Adult. Biomarkers / metabolism. Cardiovascular System / physiopathology. Heart Ventricles / abnormalities. Humans. Neurotransmitter Agents / metabolism. Ventricular Function


26. Banfi C, Ferrario S, De Vincenti O, Ceruti S, Fumagalli M, Mazzola A, D' Ambrosi N, Volontè C, Fratto P, Vitali E, Burnstock G, Beltrami E, Parolari A, Polvani G, Biglioli P, Tremoli E, Abbracchio MP: P2 receptors in human heart: upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNFalpha and potential role in myocardial cell death. J Mol Cell Cardiol; 2005 Dec;39(6):929-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P2 receptors in human heart: upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNFalpha and potential role in myocardial cell death.
  • Despite evidence suggesting roles in human heart, the map of myocardial P2 receptors is incomplete, and their involvement in chronic heart failure (CHF) has never received adequate attention.
  • In left myocardia from five to nine control and 5-12 CHF subjects undergoing heart transplantation, we analyzed the full repertoire of P2 receptors and of 10 "orphan" P2Y-like receptors.
  • The potential significance of this change was studied in primary cardiac fibroblasts freshly isolated from young pigs.
  • Exposure of cardiac fibroblasts to ATP or its hydrolysis-resistant-analog benzoylATP induced apoptosis.
  • In cardiac fibroblasts, TNFalpha inhibited the downregulation of P2X(6) mRNA associated to prolonged agonist exposure, suggesting that, by preventing ATP-induced P2X(6) desensitization, TNFalpha may abolish a defense mechanism meant at avoiding Ca(2+) overload and, ultimately, Ca(2+)-dependent cell death.
  • In conclusion, we provide the first characterization of P2 receptors in the human heart and suggest that the interaction between TNFalpha and the upregulated P2X(6) receptor may represent a novel pathogenic mechanism in CHF.
  • [MeSH-major] Down-Regulation / drug effects. Fibroblasts / metabolism. Heart Transplantation. Myocardium / metabolism. Receptors, Purinergic P2 / biosynthesis. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16242142.001).
  • [ISSN] 0022-2828
  • [Journal-full-title] Journal of molecular and cellular cardiology
  • [ISO-abbreviation] J. Mol. Cell. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; 0 / Receptors, Purinergic P2; 0 / Tumor Necrosis Factor-alpha; 0 / purinoceptor P2X6; 81790-82-1 / 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate; 8L70Q75FXE / Adenosine Triphosphate; SY7Q814VUP / Calcium
  •  go-up   go-down


27. Mielniczuk LM, Baughman KL: Immune modulation therapy in heart failure. Congest Heart Fail; 2006 Mar-Apr;12(2):91-6; quiz 97-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune modulation therapy in heart failure.
  • Several lines of evidence suggest that inflammation plays a pathogenic role in the development and progression of congestive heart failure, influencing heart contractility and hypertrophy, promoting apoptosis, and contributing to the myocardial remodeling process.
  • As the prevalence of heart failure continues to increase, novel therapeutic strategies are employed to decrease the burden of this disease.
  • Although multiple studies have suggested a potential for immunomodulatory therapy in heart failure patients, the precise role of this targeted approach still remains to be determined.
  • Further research is needed to identify the key factors in the immunopathogenesis of heart failure, identify the patients who are most likely to respond, and develop management strategies that result in consistent benefit leading to decreased morbidity and mortality in the heart failure patient population.
  • [MeSH-major] Cytokines / drug effects. Heart Failure / drug therapy. Immunoglobulins, Intravenous / therapeutic use. Immunologic Factors / therapeutic use
  • [MeSH-minor] Disease Progression. Down-Regulation / drug effects. Humans. Inflammation / metabolism. Tumor Necrosis Factor-alpha

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596043.001).
  • [ISSN] 1527-5299
  • [Journal-full-title] Congestive heart failure (Greenwich, Conn.)
  • [ISO-abbreviation] Congest Heart Fail
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors; 0 / Tumor Necrosis Factor-alpha
  • [Number-of-references] 36
  •  go-up   go-down


28. Miyamoto SD, Pietra BA, Chan KC, Ivy DD, Mashburn C, Campbell DN, Mitchell MB, Boucek MM: Long-term outcome of palliation with internal pulmonary artery bands after primary heart transplantation for hypoplastic left heart syndrome. Pediatr Cardiol; 2009 May;30(4):419-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of palliation with internal pulmonary artery bands after primary heart transplantation for hypoplastic left heart syndrome.
  • The purpose of this study was to describe the long-term outcome of infants with hypoplastic left heart syndrome (HLHS) who underwent placement of internal pulmonary artery bands as part of a transcatheter palliation procedure followed by primary heart transplantation.
  • Cardiac hemodynamics, pulmonary artery architecture, and pulmonary artery growth since transplantation are described.
  • Nine infants with HLHS had internal pulmonary artery bands placed and underwent successful heart transplant.

  • Genetic Alliance. consumer health - Hypoplastic left heart syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Heart Lung Transplant. 2005 May;24(5):576-82 [15896755.001]
  • [Cites] Ann Thorac Surg. 2005 May;79(5):1656-60; discussion 1660-1 [15854947.001]
  • [Cites] J Appl Physiol (1985). 2005 Aug;99(2):445-57 [15557009.001]
  • [Cites] Pediatr Cardiol. 2005 Mar-Apr;26(2):190-9 [15906023.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Dec;130(6):1731; author reply 1731-2 [16308032.001]
  • [Cites] Pediatr Cardiol. 2005 Nov-Dec;26(6):751-5 [16132281.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Feb;131(2):412-7 [16434272.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 May;29(5):675-81 [16581261.001]
  • [Cites] Ann Thorac Surg. 2006 Oct;82(4):1252-7; discussion 1258-9 [16996917.001]
  • [Cites] Catheter Cardiovasc Interv. 2006 Nov;68(5):719-26 [17039520.001]
  • [Cites] Acta Paediatr. 2006 Dec;95(12):1594-600 [17129968.001]
  • [Cites] Ann Thorac Surg. 2008 Jun;85(6):2063-70; discussion 2070-1 [18498821.001]
  • [Cites] Catheter Cardiovasc Interv. 2008 Nov 1;72(5):696-704 [18942130.001]
  • [Cites] Circulation. 2002 Mar 5;105(9):1099-103 [11877362.001]
  • [Cites] Heart. 2003 Jun;89(6):645-50 [12748222.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 May;23(5):735-42 [12754026.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1070-82 [12771881.001]
  • [Cites] J Thorac Cardiovasc Surg. 1984 Oct;88(4):610-9 [6482493.001]
  • [Cites] Br Heart J. 1993 Jun;69(6):551-5 [7688231.001]
  • [Cites] Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2005;:72-7 [15818361.001]
  • [Cites] Ann Thorac Surg. 2005 Jul;80(1):44-9 [15975337.001]
  • (PMID = 19365660.001).
  • [ISSN] 1432-1971
  • [Journal-full-title] Pediatric cardiology
  • [ISO-abbreviation] Pediatr Cardiol
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL084923-03; United States / NHLBI NIH HHS / HL / P50 HL084923; United States / NHLBI NIH HHS / HL / P50 HL084923-03
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS300864; NLM/ PMC3117302
  •  go-up   go-down


29. Almenar Bonet L: Spanish Heart Transplantation Registry. 20th official report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984-2008). Rev Esp Cardiol; 2009 Nov;62(11):1286-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spanish Heart Transplantation Registry. 20th official report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984-2008).
  • INTRODUCTION AND OBJECTIVES: The purpose of this article was to present the results of the heart transplantations carried out in Spain from the first use of this therapeutic modality in May 1984.
  • METHODS: A descriptive analysis of all heart transplantations performed up until December 31, 2008 was carried out.
  • The typical clinical profile of a Spanish heart transplant patient in 2008 was that of a 53-year-old male who had been diagnosed with nonrevascularizable ischemic heart disease and who had severely depressed ventricular function and a poor functional status.
  • The implanted heart typically came from a 37-year-old donor who had died from a head injury or brain hemorrhage and the average waiting time was 111 days.
  • CONCLUSIONS: The survival rate obtained with heart transplantation in Spain, especially in recent years, has made transplantation the treatment of choice for patients with end-stage heart failure and a poor functional status and for whom there are few other established medical or surgical options.
  • [MeSH-major] Heart Failure / epidemiology. Heart Failure / surgery. Heart Transplantation / statistics & numerical data. Registries

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19889340.001).
  • [ISSN] 1579-2242
  • [Journal-full-title] Revista española de cardiología
  • [ISO-abbreviation] Rev Esp Cardiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


30. Tocci G, Sciarretta S, Volpe M: Development of heart failure in recent hypertension trials. J Hypertens; 2008 Jul;26(7):1477-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of heart failure in recent hypertension trials.
  • BACKGROUND: Heart failure represents a major cause of disease burden worldwide and is expected to further rise in the coming decades.
  • Hypertension is the clinical condition most frequently associated to heart failure.
  • OBJECTIVE: To systematically review the incidence of heart failure compared to coronary heart diseases and stroke in recent hypertension trials.
  • METHODS: We identified 23 trials concluded within the last decade including 193,424 patients with hypertension or at 'high' cardiovascular risk with a predominant presence of hypertensive patients, and reported incidence of major cardiovascular events, including heart failure, coronary heart disease and stroke.
  • RESULTS: A total of 24 837 major cardiovascular events were recorded in trials performed between 1997 and 2007, of which 7171 (28.9%) were cases of heart failure, 10,223 (41.1%) of coronary heart disease and 7443 (30.0%) of stroke.
  • The rate of heart failure was comparable with that of stroke, accounting for 8.5 and 9.1 events per 1000 patients (P = NS), respectively.
  • Heart failure development was more prevalent in older subjects (>65 years) [odds ratio: 3.08, confidence interval 95% (2.88-3.31); P < 0.0001], in black versus nonblack individuals [odds ratio 1.90, (1.76-2.06); P < 0.0001], in diabetic versus nondiabetic patients [odds ratio 4.91, 95% confidence interval (4.40-5.43); P < 0.0001] and in patients with 'very high' risk versus those with a 'high' risk profile [odds ratio 1.29, 95% confidence interval (1.23-1.36); P < 0.0001].
  • CONCLUSION: Our analysis shows that heart failure development remains a major problem in hypertension.
  • In recent trials on hypertension, the development of heart failure was found comparable with that of stroke: it is more prevalent in older, black, diabetic and 'very high' risk individuals.
  • These findings highlight the relevance of heart failure development in hypertension and support the need for optimizing antihypertensive strategies aimed at preventing the progression to overt heart failure, thus reducing the growing burden of disease associated with hypertension.
  • [MeSH-major] Heart Failure / epidemiology. Hypertension / complications

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551026.001).
  • [ISSN] 0263-6352
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  • [Number-of-references] 75
  •  go-up   go-down


31. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA: Carcinoid heart disease. Prog Cardiovasc Dis; 2007 May-Jun;49(6):439-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid heart disease.
  • Carcinoid heart disease is a rare form of valvular heart disease.
  • The management of these patients is complex, as the systemic malignant disease and the cardiac involvement have to be considered at the same time.
  • Development and progression of carcinoid heart disease are associated with increased morbidity and mortality.
  • In patients with severe cardiac involvement and well-controlled systemic disease, cardiac surgery has been recognized as the only effective treatment option.
  • Valve replacement surgery may not only be beneficial in terms of symptom relief, but may also contribute to the improved survival observed over the past 2 decades in patients with carcinoid heart disease.
  • Early diagnosis and early surgical treatment in appropriately selected patients may provide the best results.
  • In this article, we review the current literature regarding the biology, diagnosis, treatment, and prognosis of carcinoid heart disease.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Heart Disease / therapy. Cardiac Surgical Procedures. Cardiovascular Agents / therapeutic use. Embolization, Therapeutic. Fluid Therapy. Hepatectomy. Malignant Carcinoid Syndrome / therapy

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498524.001).
  • [ISSN] 0033-0620
  • [Journal-full-title] Progress in cardiovascular diseases
  • [ISO-abbreviation] Prog Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers; 0 / Cardiovascular Agents; 54-16-0 / Hydroxyindoleacetic Acid
  • [Number-of-references] 79
  •  go-up   go-down


32. Gartner GE, Hicks JW, Manzani PR, Andrade DV, Abe AS, Wang T, Secor SM, Garland T Jr: Phylogeny, ecology, and heart position in snakes. Physiol Biochem Zool; 2010 Jan-Feb;83(1):43-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phylogeny, ecology, and heart position in snakes.
  • A previous nonphylogenetic analysis of heart position in snakes-which often assume vertical postures-found the heart located 15%-25% of total body length from the head in terrestrial and arboreal species but 25%-45% in aquatic species.
  • It was hypothesized that a more anterior heart in arboreal species served to reduce the hydrostatic blood pressure when these animals adopt vertical postures during climbing, whereas an anterior heart position would not be needed in aquatic habitats, where the effects of gravity are less pronounced.
  • General linear models regressing log(10) snout-heart position on log(10) snout-vent length (SVL), as well as dummy variables coding for habitat and/or clade, were compared using likelihood ratio tests and the Akaike Information Criterion.
  • Heart distance to the tip of the snout scaled isometrically with SVL.
  • The best-fit model predicting snake heart position included aspects of both habitat and clade and indicated that arboreal snakes in our study tend to have hearts placed more posteriorly, opposite the trend identified in previous studies.
  • Phylogenetic signal in relative heart position was apparent both within and among clades.
  • Our results suggest that overcoming gravitational pressure gradients in snakes most likely involves the combined action of several cardiovascular and behavioral adaptations in addition to alterations in relative heart location.
  • [MeSH-major] Ecosystem. Heart / anatomy & histology. Phylogeny. Snakes / anatomy & histology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Physiol Biochem Zool. 2011 Jan-Feb;84(1):99-101; discussion 102-6 [21162675.001]
  • (PMID = 19968564.001).
  • [ISSN] 1537-5293
  • [Journal-full-title] Physiological and biochemical zoology : PBZ
  • [ISO-abbreviation] Physiol. Biochem. Zool.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Szymański P, Klisiewicz A, Lubiszewska B, Lipczyńska M, Michałek P, Janas J, Hoffman P: Application of classic heart failure definitions of asymptomatic and symptomatic ventricular dysfunction and heart failure symptoms with preserved ejection fraction to patients with systemic right ventricles. Am J Cardiol; 2009 Aug 1;104(3):414-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of classic heart failure definitions of asymptomatic and symptomatic ventricular dysfunction and heart failure symptoms with preserved ejection fraction to patients with systemic right ventricles.
  • Heart failure guidelines classify patients into subgroups with asymptomatic versus symptomatic ventricular dysfunction versus heart failure with a preserved ejection fraction.
  • Heart failure symptoms with preserved systolic function were present in 5 patients (11.9%), including 3 patients with significant TR.
  • In conclusion, asymptomatic RV dysfunction and heart failure symptoms with preserved systolic function are common in patients with systemic right ventricles.
  • Heart failure symptoms with preserved RV systolic function can be frequently explained by the coexistence of significant TR.
  • [MeSH-major] Heart Failure / classification. Heart Failure / physiopathology. Tricuspid Valve Insufficiency / physiopathology. Ventricular Dysfunction, Right / physiopathology. Ventricular Function, Right / physiology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19616677.001).
  • [ISSN] 1879-1913
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Wein S, Voskoboinik A, Wein L, Billah B, Krum H: Extending the boundaries of cardiac resynchronization therapy: efficacy in atrial fibrillation, New York heart association class II, and narrow QRS heart failure patients. J Card Fail; 2010 May;16(5):432-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extending the boundaries of cardiac resynchronization therapy: efficacy in atrial fibrillation, New York heart association class II, and narrow QRS heart failure patients.
  • BACKGROUND: Large-scale clinical trials have demonstrated the benefits of cardiac resynchronization therapy (CRT) in patients with New York Heart Association (NYHA) Class III/IV heart failure, systolic left ventricular dysfunction, and a wide QRS.
  • METHODS AND RESULTS: We meta-analyzed clinical benefits of CRT in heart failure patients with narrow QRS, atrial fibrillation (AF) and NYHA Class II symptoms.
  • CONCLUSIONS: Large-scale clinical outcome trials of CRT are warranted in heart failure patients with narrow QRS, AF, and NYHA II, given the similar benefits observed to those with wide QRS, SR, and NYHA III/IV for many parameters.
  • [MeSH-major] Atrial Fibrillation / therapy. Cardiac Pacing, Artificial. Heart Failure / therapy


35. Book WM: Heart failure in the adult patient with congenital heart disease. J Card Fail; 2005 May;11(4):306-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart failure in the adult patient with congenital heart disease.
  • BACKGROUND: Adult survival is now the rule for most congenital heart defects.
  • However, despite surgical "repair," heart failure remains a common long-term complication of congenital heart disease.
  • Heart failure specialists are seeing an increasing number of patients with congenital defects as the underlying etiology of their heart failure.
  • CONCLUSION: This review discusses the diagnosis, pathophysiology, and management of the adult congenital heart patient with concomitant heart failure.
  • [MeSH-major] Heart Defects, Congenital / complications. Heart Failure / etiology


36. Ueda K, Ikeda T, Iwanaga N, Katsuragi S, Yamanaka K, Neki R, Yoshimatsu J, Shiraishi I: Intrapartum fetal heart rate monitoring in cases of congenital heart disease. Am J Obstet Gynecol; 2009 Jul;201(1):64.e1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrapartum fetal heart rate monitoring in cases of congenital heart disease.
  • OBJECTIVE: We evaluated the intrapartum fetal heart rate (FHR) patterns in fetuses with congenital heart disease (CHD).
  • We suggest that cardiac abnormalities are associated with abnormalities in FHR patterns.
  • [MeSH-major] Fetal Diseases / physiopathology. Heart Defects, Congenital / physiopathology. Heart Rate, Fetal / physiology


37. Ksela J, Kalisnik JM, Avbelj V, Vidmar G, Suwalski P, Suwalski G, Suwalski K, Gersak B: Short- versus long-term ECG recordings for the assessment of non-linear heart rate variability parameters after beating heart myocardial revascularization. Comput Biol Med; 2009 Jan;39(1):79-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short- versus long-term ECG recordings for the assessment of non-linear heart rate variability parameters after beating heart myocardial revascularization.
  • Non-linear analyses of heart rate dynamics reveal subtle changes not evident from conventional heart rate variability measures.
  • In 67 patients revascularized with beating-heart technique, fractal dimension and detrended fluctuation analyses were obtained from 24-hour Holter and 15-minute high-resolution ECG recordings pre and postoperatively.
  • [MeSH-major] Electrocardiography / methods. Heart Rate. Myocardial Revascularization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147125.001).
  • [ISSN] 1879-0534
  • [Journal-full-title] Computers in biology and medicine
  • [ISO-abbreviation] Comput. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ishizawar D, Yancy C: Racial differences in heart failure therapeutics. Heart Fail Clin; 2010 Jan;6(1):65-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial differences in heart failure therapeutics.
  • Heart failure in African Americans has a phenotype that is distinct from that in non-African Americans and that demonstrates increased importance of hypertensive etiologies.
  • Despite differences in the heart failure phenotype, therapy of heart failure in African Americans remains largely the same as in white heart failure cohorts, with the notable exception of the added benefits provided by combination of hydralazine and isosorbide dinitrate (HYD-ISDN), now regarded as highly indicated therapy by both the Heart Failure Society of America and the American College of Cardiology/American Heart Association heart failure guideline committees.
  • [MeSH-major] African Americans / genetics. Heart Failure / drug therapy. Heart Failure / genetics

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. HYDRALAZINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ISOSORBIDE DINITRATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19945062.001).
  • [ISSN] 1551-7136
  • [Journal-full-title] Heart failure clinics
  • [ISO-abbreviation] Heart Fail Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Antihypertensive Agents; 0 / Drug Combinations; 0 / Nitric Oxide Donors; 0 / isosorbide-hydralazine combination; 26NAK24LS8 / Hydralazine; 31C4KY9ESH / Nitric Oxide; IA7306519N / Isosorbide Dinitrate
  • [Number-of-references] 62
  •  go-up   go-down


39. Kaholokula JK, Saito E, Mau MK, Latimer R, Seto TB: Pacific Islanders' perspectives on heart failure management. Patient Educ Couns; 2008 Feb;70(2):281-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pacific Islanders' perspectives on heart failure management.
  • OBJECTIVE: To identify the health beliefs, attitudes, practices, and social and family relations important in heart failure treatment among Pacific Islanders.
  • METHODS: Four focus groups were convened with 36 Native Hawaiians and Samoans with heart failure and their family caregivers.
  • Thematic data analysis was used to categorize data into four domains: health beliefs and attitudes, preferred health practices, social support systems, and barriers to heart failure care.
  • RESULTS: Common coping styles and emotional experiences of heart failure in this population included avoidance or denial of illness, hopelessness and despair, and reliance on spiritual/religious beliefs as a means of support.
  • Two types of social support (informational and tangible-instrumental) were identified as important in heart failure care.
  • Barriers to heart failure care included poor knowledge of heart failure, lack of trust in physicians' care, poor physician-patient relations, finances, dietary changes, and competing demands on time.
  • CONCLUSION: The recruitment, retention, and adherence of Pacific Islanders to heart failure interventions is affected by an array of psychosocial and socio-cultural factors.
  • PRACTICE IMPLICATIONS: Interventions might be improved by offering participants accurate and detailed information about heart failure and its treatment, engaging the extended family in providing necessary supports, and providing tools to facilitate physician-patient relationships, among others, within the context of a larger socio-cultural system.

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Native Hawaiian and Pacific Islander Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2002 Jan 2;39(1):83-9 [11755291.001]
  • [Cites] Qual Life Res. 2001;10(8):671-82 [11871588.001]
  • [Cites] J Holist Nurs. 2002 Mar;20(1):5-25; quiz 26-30 [11898688.001]
  • [Cites] Patient Educ Couns. 2002 Apr;46(4):287-95 [11932128.001]
  • [Cites] J Subst Abuse Treat. 2002 Apr;22(3):109-19 [12039613.001]
  • [Cites] Cancer Pract. 2002 Jul-Aug;10(4):192-200 [12100103.001]
  • [Cites] Pac Health Dialog. 2001 Sep;8(2):274-9 [12180506.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2002 Oct;252(5):240-9 [12451467.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):347-52 [12578516.001]
  • [Cites] Eur J Heart Fail. 2003 Mar;5(2):201-9 [12644013.001]
  • [Cites] Health Educ Behav. 2003 Apr;30(2):133-46 [12693519.001]
  • [Cites] Diabetes Educ. 1999 May-Jun;25(3):351-63 [10531855.001]
  • [Cites] Control Clin Trials. 2000 Oct;21(5 Suppl):200S-5S [11018576.001]
  • [Cites] Prev Med. 2000 Nov;31(5):529-37 [11071833.001]
  • [Cites] Med Care Res Rev. 2000;57 Suppl 1:108-45 [11092160.001]
  • [Cites] Health Serv Res. 2003 Jun;38(3):809-29 [12822914.001]
  • [Cites] J Natl Med Assoc. 2003 Oct;95(10):955-63 [14620708.001]
  • [Cites] Altern Ther Health Med. 2003 Nov-Dec;9(6):64-9 [14618860.001]
  • [Cites] Nurs Res. 2003 Nov-Dec;52(6):361-9 [14639082.001]
  • [Cites] Addict Behav. 2004 Jan;29(1):127-41 [14667425.001]
  • [Cites] Eur J Cardiovasc Nurs. 2003 Dec;2(4):255-64 [14667481.001]
  • [Cites] Aging Ment Health. 2004 Jan;8(1):83-91 [14690872.001]
  • [Cites] J Psychosom Res. 2004 Jan;56(1):95-101 [14987970.001]
  • [Cites] J Manag Care Pharm. 2004 Mar;10(2 Suppl):S2-7 [15046544.001]
  • [Cites] Med Clin North Am. 2004 Sep;88(5):1347-68, xii-xiii [15331320.001]
  • [Cites] J Transcult Nurs. 2004 Oct;15(4):291-7 [15359062.001]
  • [Cites] Altern Ther Health Med. 2004 Sep-Oct;10(5):58-64 [15478787.001]
  • [Cites] Am Heart J. 1999 May;137(5):919-27 [10220642.001]
  • [Cites] J Psychosom Res. 2004 Dec;57(6):573-81 [15596164.001]
  • [Cites] Womens Health Issues. 2005 Jan-Feb;15(1):5-13 [15661582.001]
  • [Cites] Eur J Heart Fail. 2005 Jun;7(4):592-603 [15921800.001]
  • [Cites] Am Heart J. 2005 Sep;150(3):448-54 [16169322.001]
  • [Cites] Pac Health Dialog. 2004 Sep;11(2):120-30 [16281689.001]
  • [Cites] Pac Health Dialog. 2004 Sep;11(2):176-82 [16281697.001]
  • [Cites] Eur J Cardiovasc Nurs. 2005 Dec;4(4):298-307 [15893959.001]
  • [Cites] J Am Diet Assoc. 2006 Feb;106(2):209-10 [16442867.001]
  • [Cites] Circulation. 2006 Feb 14;113(6):e85-151 [16407573.001]
  • [Cites] Med Care. 2006 May;44(5 Suppl):I64-72 [16625066.001]
  • [Cites] Nurs Res. 2006 May-Jun;55(3):180-8 [16708042.001]
  • [Cites] Hawaii Med J. 2006 May;65(5):130-2, 134-139, 151 [16774141.001]
  • [Cites] J Card Fail. 2006 Sep;12(7):546-53 [16952789.001]
  • [Cites] Prog Cardiovasc Nurs. 2006 Summer;21(3):128-33 [16957458.001]
  • [Cites] Am J Cardiol. 2006 Oct 15;98(8):1069-72 [17027573.001]
  • [Cites] Int Psychogeriatr. 2006 Dec;18(4):577-95 [16686964.001]
  • [Cites] J Card Fail. 2006 Oct;12(8):621-7 [17045181.001]
  • [Cites] Am Heart J. 2006 Nov;152(5):940.e1-8 [17070164.001]
  • [Cites] Prog Cardiovasc Nurs. 2006 Fall;21(4):202-11 [17170596.001]
  • [Cites] J Aging Health. 2007 Feb;19(1):22-38 [17215200.001]
  • [Cites] Psychosom Med. 2007 Jan;69(1):23-9 [17244845.001]
  • [Cites] J Cardiovasc Nurs. 2007 Mar-Apr;22(2):125-30 [17318038.001]
  • [Cites] Arch Intern Med. 2007 Feb 26;167(4):367-73 [17325298.001]
  • [Cites] Complement Ther Med. 2007 Mar;15(1):21-9 [17352968.001]
  • [Cites] J Gen Intern Med. 2007 Apr;22(4):470-7 [17372795.001]
  • [Cites] Health Technol Assess. 2007 Apr;11(15):1-157, iii [17459263.001]
  • [Cites] Ethn Health. 2007 Sep;12(4):381-400 [17701763.001]
  • [Cites] Health Policy. 2007 Oct;83(2-3):332-42 [17367892.001]
  • [Cites] Br J Gen Pract. 2005 Jan;55(510):26-31 [15667762.001]
  • [Cites] Health Serv Res. 2005 Apr;40(2):517-37 [15762905.001]
  • [Cites] Patient Educ Couns. 2005 Jun;57(3):300-7 [15893212.001]
  • (PMID = 18068939.001).
  • [ISSN] 0738-3991
  • [Journal-full-title] Patient education and counseling
  • [ISO-abbreviation] Patient Educ Couns
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / L60 MD001355; United States / NHLBI NIH HHS / HL / U01 HL079163-02; United States / NHLBI NIH HHS / HL / HL079163-02S1; United States / NHLBI NIH HHS / HL / HL079163-03; United States / NHLBI NIH HHS / HL / HL079163-01; United States / NIMHD NIH HHS / MD / L60 MD001355-01; United States / NIMHD NIH HHS / MD / MD001355-01; United States / NIMHD NIH HHS / MD / MD001355-02; United States / NHLBI NIH HHS / HL / HL079163-02; United States / NHLBI NIH HHS / HL / U01 HL079163; United States / NHLBI NIH HHS / HL / U01 HL079163-01; United States / NHLBI NIH HHS / HL / U01 HL079163-02S1; United States / NIMHD NIH HHS / MD / P20 MD000173; United States / NIMHD NIH HHS / MD / L60 MD001355-02; United States / NHLBI NIH HHS / HL / U01 HL079163-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Other-IDs] NLM/ NIHMS39550; NLM/ PMC2254651
  •  go-up   go-down


40. Giannakoulas G, Dimopoulos K: Exercise training in congenital heart disease: should we follow the heart failure paradigm? Int J Cardiol; 2010 Jan 21;138(2):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exercise training in congenital heart disease: should we follow the heart failure paradigm?
  • Exercise intolerance is common in adults with congenital heart disease (ACHD) and affects their prognosis and quality of life, thus becoming an important target for therapies.
  • While exercise training has been widely studied in chronic heart failure, its safety and efficacy in ACHD remain unknown.
  • [MeSH-major] Exercise Therapy. Heart Defects, Congenital / physiopathology. Heart Defects, Congenital / therapy. Heart Failure / therapy. Quality of Life


41. Cotter G, Cotter OM, Kaluski E: Hemodynamic monitoring in acute heart failure. Crit Care Med; 2008 Jan;36(1 Suppl):S40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemodynamic monitoring in acute heart failure.
  • Hemodynamic monitoring has moved in the last few years from being the holy grail of evaluating patients with acute heart failure to being all but extinct.
  • Recent studies have not demonstrated any sustained benefits from right heart catheterization, and some studies have even suggested harm due to adverse events related to this invasive procedure.
  • It is possible that this lack of efficacy is related to multiple inherent deficiencies in the design of these studies, including the inclusion of patients with chronic heart failure or mild acute heart failure, use of the reduction in pulmonary artery occlusion pressure as the main hemodynamic target for intervention, choice of treatment algorithms, and selection of ambitious long-term efficacy and safety end points.
  • This review discusses the role of hemodynamic monitoring in patients with acute heart failure.
  • We suggest that right heart catheterization should be reserved for patients with acute heart failure and impending respiratory or circulatory failure especially in the presence of a diagnostic or therapeutic dilemma or when encountering acute heart failure or hemodynamic lability refractory to conventional therapy.
  • [MeSH-major] Heart Failure / physiopathology. Hemodynamics. Monitoring, Physiologic
  • [MeSH-minor] Acute Disease. Algorithms. Cardiac Catheterization. Humans

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158476.001).
  • [ISSN] 1530-0293
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


42. Santos DG, Resende MF, Mill JG, Mansur AJ, Krieger JE, Pereira AC: Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure. BMC Med Genet; 2010;11:89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure.
  • BACKGROUND: Cardiac remodeling is generally an adverse sign and is associated with heart failure (HF) progression.
  • NFkB, an important transcription factor involved in many cell survival pathways, has been implicated in the remodeling process, but its role in the heart is still controversial.
  • The purpose of this study was to evaluate the association of this polymorphism with clinical and functional characteristics of heart failure patients of different etiologies.
  • However, our data suggest that a diminished activation of NFKB1, previously associated with the ATTG1/ATTG1 genotype, may act modulating on the onset of disease and, once the individual has HF, the genotype may modulate disease severity by increasing cardiac remodeling and function deterioration.
  • [MeSH-major] Heart Failure / genetics. NF-kappa B p50 Subunit / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Aged. Alleles. Cardiomyopathy, Dilated / genetics. Cohort Studies. Female. Follow-Up Studies. Gene Frequency. Genetic Predisposition to Disease. Genotype. Heart Ventricles / physiopathology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6842-4 [10602459.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6853-66 [10602461.001]
  • [Cites] J Am Coll Cardiol. 2000 Mar 1;35(3):569-82 [10716457.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):3-6 [11134170.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):7-11 [11134171.001]
  • [Cites] J Am Coll Cardiol. 2001 Aug;38(2):307-14 [11499717.001]
  • [Cites] Circulation. 2002 Oct 29;106(18):2351-7 [12403666.001]
  • [Cites] Hum Mol Genet. 2004 Jan 1;13(1):35-45 [14613970.001]
  • [Cites] Circulation. 2003 Dec 23;108(25):3075-8 [14676146.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] N Engl J Med. 1971 Dec 23;285(26):1441-6 [5122894.001]
  • [Cites] Circulation. 1978 Dec;58(6):1072-83 [709763.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Circulation. 1994 Jan;89(1):68-75 [8281697.001]
  • [Cites] Genomics. 1995 Dec 10;30(3):493-505 [8825636.001]
  • [Cites] Circulation. 1998 Jul 14;98(2):100-3 [9679714.001]
  • [Cites] Cardiovasc Res. 1998 Aug;39(2):434-41 [9798528.001]
  • [Cites] Clin Chem. 1999 Jan;45(1):7-17 [9895331.001]
  • [Cites] Cardiovasc Res. 2005 Jun 1;66(3):520-9 [15914117.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H466-76 [15695559.001]
  • [Cites] J Am Coll Cardiol. 2005 Sep 20;46(6):e1-82 [16168273.001]
  • [Cites] Atherosclerosis. 2006 Jan;184(1):193-200 [15916766.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1337-44 [16632551.001]
  • [Cites] FASEB J. 2006 Sep;20(11):1918-20 [16837548.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):507-12 [17556593.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2320-7 [17644577.001]
  • [Cites] Circ Res. 2008 Feb 1;102(2):257-64 [18007026.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(8):1425-30 [17693123.001]
  • [Cites] Circ Res. 2009 Mar 13;104(5):699-706 [19168865.001]
  • [Cites] BMC Med Genet. 2009;10:47 [19480714.001]
  • [Cites] Circ Res. 2009 Jul 2;105(1):70-9 [19478205.001]
  • (PMID = 20534156.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B p50 Subunit; 0 / NFKB1 protein, human
  • [Other-IDs] NLM/ PMC2897791
  •  go-up   go-down


43. [Treatment of diastolic heart failure]. Georgian Med News; 2007 Dec;(153):18-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of diastolic heart failure].
  • The review contains literature data about the treatment of diastolic heart failure.
  • The analyses of retrospective and current sources of information revealed that there is no unified approach to the treatment at diastolic heart failure.
  • It was emphasized that heart diastolic and systolic failure should be treated differently.
  • Actually, no specific recommendations of heart diastolic failure treatment exist.
  • Theoretical recommendations on the necessity of combined symptomatic, causal, and improving the prognosis treatment for diastolic heart failure were proposed.
  • [MeSH-major] Heart Failure, Diastolic / drug therapy. Nitroprusside / therapeutic use. Vasodilator Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250490.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Vasodilator Agents; 169D1260KM / Nitroprusside
  • [Number-of-references] 23
  •  go-up   go-down


44. Masson S, Latini R, Milani V, Moretti L, Rossi MG, Carbonieri E, Frisinghelli A, Minneci C, Valisi M, Maggioni AP, Marchioli R, Tognoni G, Tavazzi L, GISSI-HF Investigators: Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial. Circ Heart Fail; 2010 Jan;3(1):65-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial.
  • BACKGROUND: Increased urinary excretion of albumin is an early sign of kidney damage and a risk factor for progressive cardiovascular and renal diseases and heart failure.
  • There is, however, only limited information on the prevalence and prognostic role of urinary albumin excretion in patients with established chronic heart failure.
  • METHODS AND RESULTS: A total of 2131 patients enrolled in 76 sites participating in the GISSI-Heart Failure trial provided a first morning spot sample of urine at any of the clinical visits scheduled in the trial to calculate the urinary albumin-to-creatinine ratio.
  • CONCLUSIONS: Independently of diabetes, hypertension, or renal function, elevated albumin excretion is a powerful prognostic marker in patients with chronic heart failure.
  • [MeSH-major] Albuminuria. Heart Failure / diagnosis. Heart Failure / urine

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850697.001).
  • [ISSN] 1941-3297
  • [Journal-full-title] Circulation. Heart failure
  • [ISO-abbreviation] Circ Heart Fail
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Roncarolo PL; Moretti L; Gregori G; Zanetta M; Boni S; Porcu M; Pettinati G; Ciricugno S; Caliendo L; Leonardi G; Perticone F; Raccagni D; Severini D; Carlon R; Cosmi F; Cosmi D; Misuraca G; Barbieri A; Buia E; Minneci C; Stella L; Malinverni C; Pende A; Caruso D; Volpi A; Jones N; Buccolieri M; Tagliamonte E; Rigatelli G; Barbiero M; Portulano V; Scillabra G; Di Tano G; Beretta L; Margonato A; Coppolino C; Sarto P; Aiolfi E; Musca G; Perrone Filardi P; Girardi P; Campaniello C; Lucchina PG; Montagna L; Geraci G; Floresta M; Ingrillì F; Frisinghelli A; Palvarini M; Opasich C; Gualco A; Revera M; Battista R; De Risi L; Mazzucco R; Milan D; Ruggeri A; Piovaccari G; Provenzano A; Varveri A; Carbonieri E; Rossi I; Mos L; Partesana N; Cucchi G; Anastasio L; Bernardinangeli M; Proietti G; Massobrio N; Imazio M; Fenoil R; Gabasio S; Cioffi G; Ghezzi I; Barbuzzi S; Gubelli S; Giannuzzi P; Mezzani A; Graziano G; Moccetti T; Rossi MG; Tavazzi L; Tognoni G; Franzosi MG; Latini R; Maggioni AP; Marchioli R; Nicolosi GL; Porcu M; Geraci E; Scherillo M; Fabbri G; Bartolomei B; Bertoli D; Cobelli F; Fresco C; Ledda A; Levantesi G; Opasich C; Rusconi F; Sinagra G; Turazza F; Volpi A
  •  go-up   go-down


45. Handoko ML, Lamberts RR, Redout EM, de Man FS, Boer C, Simonides WS, Paulus WJ, Westerhof N, Allaart CP, Vonk-Noordegraaf A: Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol; 2009 Nov;297(5):H1752-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart.
  • Right heart failure in pulmonary arterial hypertension (PH) is associated with mechanical ventricular dyssynchrony, which leads to impaired right ventricular (RV) function and, by adverse diastolic interaction, to impaired left ventricular (LV) function as well.
  • Chronic PH with right heart failure was induced in rats by injection of monocrotaline (80 mg/kg).
  • To validate for PH-related ventricular dyssynchrony, rats (6 PH, 6 controls) were examined by cardiac magnetic resonance imaging (9.4 T), 23 days after monocrotaline or sham injection.
  • In a second group (10 PH, 4 controls), the effects of RV pacing were studied in detail, using Langendorff-perfused heart preparations.
  • [MeSH-major] Cardiac Pacing, Artificial. Heart Failure / therapy. Hypertension, Pulmonary / therapy. Ventricular Dysfunction, Right / therapy. Ventricular Function, Right
  • [MeSH-minor] Animals. Chronic Disease. Disease Models, Animal. Heart Septum / pathology. Heart Septum / physiopathology. In Vitro Techniques. Magnetic Resonance Imaging. Male. Monocrotaline. Myocardial Contraction. Perfusion. Rats. Reproducibility of Results. Time Factors. Ventricular Function, Left. Ventricular Pressure

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • Hazardous Substances Data Bank. MONOCROTALINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734361.001).
  • [ISSN] 1522-1539
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 73077K8HYV / Monocrotaline
  •  go-up   go-down


46. Niwa K, Tateno S, Akagi T, Himeno W, Kawasoe Y, Tatebe S, Matsuo K, Gatzoulis MA, Nakazawa M: Arrhythmia and reduced heart rate variability during pregnancy in women with congenital heart disease and previous reparative surgery. Int J Cardiol; 2007 Nov 15;122(2):143-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arrhythmia and reduced heart rate variability during pregnancy in women with congenital heart disease and previous reparative surgery.
  • Heart rate variability (HRV) is a significant marker of autonomic nervous function and may predict tachyarrhythmia.
  • HRV and incidence of arrhythmia in women with repaired congenital heart disease (CHD) during pregnancy were examined.
  • CONCLUSIONS: Impaired autonomic nervous activity, volume overload of the heart and operative scar all play a contributory role in higher incidence of tachyarrhythmia during pregnancy in patients with repaired CHD compared to healthy pregnant controls.
  • [MeSH-major] Heart Defects, Congenital / physiopathology. Heart Rate / physiology. Pregnancy Complications, Cardiovascular / physiopathology


47. Davis MP, Albert NM, Young JB: Palliation of heart failure. Am J Hosp Palliat Care; 2005 May-Jun;22(3):211-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliation of heart failure.
  • Heart failure is the major cause of morbidity and mortality in the United States.
  • Stage D heart failure has a greater mortality rate than many cancers and has equivalent symptom burden and severity.
  • There has been a paradigm shift in our understanding of the pathophysiology of heart failure.
  • Progressive heart failure is associated with ventricular remodeling and a maladaptive neurohumoral response.
  • Despite combination drug and device therapies, the management of Stage D heart failure includes palliation.
  • [MeSH-major] Heart Failure / therapy. Palliative Care / standards. Ventricular Dysfunction, Left / therapy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909784.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiovascular Agents
  • [Number-of-references] 78
  •  go-up   go-down


48. Ozer MK, Parlakpinar H, Cigremis Y, Ucar M, Vardi N, Acet A: Ischemia-reperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: can caffeic acid phenethyl ester (CAPE) protect the heart? Mol Cell Biochem; 2005 May;273(1-2):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ischemia-reperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: can caffeic acid phenethyl ester (CAPE) protect the heart?
  • During restoration of blood flow of the ischemic heart induced by coronary occlusion, free radicals cause lipid peroxidation with myocardial injury.
  • This experimental study assessed the preventive effect of caffeic acid phenthyl ester (CAPE), antioxidant, on I/R-induced lipid peroxidation in the rat heart.
  • In addition, we also examined morphologic changes in the heart by using light microscopy.
  • At the end of the reperfusion period, rats were sacrificed, and the heart was quickly removed for biochemical determination and histopathological analysis.
  • I/R was accompanied by a significant increase in MDA production and decrease in GSH content in the rat heart.
  • These findings imply that I/R plays a causal role in heart injury due to overproduction of oxygen radicals or insufficient antioxidant and CAPE exert cardioprotective effects probably by the radical scavenging and antioxidant activities.
  • [MeSH-major] Antioxidants / pharmacology. Caffeic Acids / pharmacology. Glutathione / metabolism. Heart / drug effects. Malondialdehyde / metabolism. Myocardial Ischemia / prevention & control. Myocardial Reperfusion Injury / metabolism. Phenylethyl Alcohol / analogs & derivatives
  • [MeSH-minor] Animals. Cardiotonic Agents / pharmacology. Cardiotonic Agents / therapeutic use. Free Radicals / metabolism. Lipid Peroxidation / drug effects. Male. Myocytes, Cardiac / drug effects. Myocytes, Cardiac / metabolism. NF-kappa B / antagonists & inhibitors. Oxidative Stress. Oxygen / metabolism. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. 2-PHENYLETHANOL .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioorg Khim. 1995 Feb;21(2):143-51 [7538294.001]
  • [Cites] Acta Physiol Scand. 2001 May;172(1):1-10 [11437734.001]
  • [Cites] Circ Res. 1984 Mar;54(3):277-85 [6697450.001]
  • [Cites] J Pediatr Surg. 1999 Oct;34(10):1458-62 [10549747.001]
  • [Cites] J Mol Cell Cardiol. 1991 Dec;23(12):1359-74 [1811055.001]
  • [Cites] Biochem J. 1985 Mar 1;226(2):545-9 [3994671.001]
  • [Cites] J Mol Cell Cardiol. 1992 Nov;24(11):1215-20 [1362226.001]
  • [Cites] J Biol Chem. 1990 Sep 25;265(27):16088-95 [2168879.001]
  • [Cites] J Appl Toxicol. 1999 Jan-Feb;19(1):55-9 [9989478.001]
  • [Cites] Circulation. 1989 Nov;80(5):1115-27 [2553296.001]
  • [Cites] Biochem Pharmacol. 1992 Sep 25;44(6):1193-9 [1417941.001]
  • [Cites] Ophthalmic Res. 1999;31(6):426-31 [10474071.001]
  • [Cites] Cardiovasc Res. 1992 Jul;26(7):641-55 [1423428.001]
  • [Cites] Can J Physiol Pharmacol. 1993 Oct-Nov;71(10-11):811-7 [8143239.001]
  • [Cites] Clin Biochem. 2004 Aug;37(8):702-5 [15302615.001]
  • [Cites] Am J Physiol. 1993 Aug;265(2 Pt 2):H484-93 [8368352.001]
  • [Cites] Urol Res. 2001 Jun;29(3):190-3 [11482445.001]
  • [Cites] Urol Res. 2000 Dec;28(6):360-3 [11221913.001]
  • [Cites] Am J Physiol. 1984 Jun;246(6 Pt 2):H776-83 [6331179.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1905-12 [10585102.001]
  • [Cites] Circulation. 1989 Nov;80(5):1449-57 [2805276.001]
  • [Cites] Life Sci. 1993;52(14):1217-23 [8450714.001]
  • [Cites] Fitoterapia. 2002 Nov;73 Suppl 1:S21-9 [12495706.001]
  • [Cites] Am J Physiol. 1991 May;260(5 Pt 2):H1395-405 [2035661.001]
  • [Cites] Mech Ageing Dev. 2001 May 15;122(6):503-18 [11295168.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Oct;16(4):458-63 [10571095.001]
  • [Cites] Annu Rev Biochem. 1983;52:711-60 [6137189.001]
  • [Cites] Acta Physiol Scand. 1994 Jul;151(3):279-90 [7976401.001]
  • [Cites] Curr Pharm Des. 2004;10(14):1699-711 [15134567.001]
  • [Cites] J Clin Invest. 1988 Apr;81(4):1297-301 [3127425.001]
  • [Cites] FEBS Lett. 1993 Aug 23;329(1-2):21-4 [7689063.001]
  • [Cites] Eur Heart J. 1986 May;7 Suppl A:3-12 [3720774.001]
  • [Cites] J Pineal Res. 2002 Nov;33(4):234-8 [12390506.001]
  • (PMID = 16013452.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Caffeic Acids; 0 / Cardiotonic Agents; 0 / Free Radicals; 0 / NF-kappa B; 4Y8F71G49Q / Malondialdehyde; G960R9S5SK / caffeic acid phenethyl ester; GAN16C9B8O / Glutathione; ML9LGA7468 / Phenylethyl Alcohol; S88TT14065 / Oxygen
  •  go-up   go-down


49. Kaye D, Esler M: Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res; 2005 May 1;66(2):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sympathetic neuronal regulation of the heart in aging and heart failure.
  • The documentation of preferential activation of the cardiac sympathetic outflow in patients with heart failure swept aside an entrenched notion that there was a functional sympathetic denervation of the failing heart and provided a theoretical basis for the clinical evaluation of beta-adrenergic blocker therapy in this condition.
  • The demonstration that heightened sympathetic nervous system activity is central to the pathogenesis and progression of congestive heart failure (CHF) has now led to the rational use of beta-adrenoceptor blockade in CHF.
  • More recently, it has also emerged that the aging heart exhibits some of the characteristic changes in autonomic control which are seen in CHF.
  • Accordingly, alterations in cardiac sympathetic nerve function are now thought to contribute also to the pathophysiology of the aging heart.
  • Furthermore, there is evidence that in humans, sympathoexcitatory rostral projections of brainstem noradrenergic neurons to the forebrain are important in the sympathetic nervous activation of both heart failure and aging.
  • Given these similarities, in this review we compare and contrast the neurobiology of the sympathetic nervous system in the failing heart and the healthy, aging heart, and consider whether the sympathetic activation accompanying aging may, perhaps, underlie and contribute to the neural pathophysiology of heart failure.
  • [MeSH-major] Aging / physiology. Heart / physiopathology. Heart Failure / physiopathology. Myocardial Contraction / physiology. Sympathetic Nervous System / physiology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820194.001).
  • [ISSN] 0008-6363
  • [Journal-full-title] Cardiovascular research
  • [ISO-abbreviation] Cardiovasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Receptors, Adrenergic; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  • [Number-of-references] 59
  •  go-up   go-down


50. Møller S, Dümcke CW, Krag A: The heart and the liver. Expert Rev Gastroenterol Hepatol; 2009 Feb;3(1):51-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The heart and the liver.
  • Cardiac failure affects the liver and liver dysfunction affects the heart.
  • Chronic and acute heart failure can lead to cardiac cirrhosis and cardiogenic ischemic hepatitis.
  • These conditions may impair liver function and treatment should be directed towards the primary heart disease and seek to secure perfusion of vital organs.
  • In patients with advanced cirrhosis, physical and/or pharmacological stress may reveal a reduced cardiac performance with systolic and diastolic dysfunction and electrophysical abnormalities, termed cirrhotic cardiomyopathy.
  • Pathophysiological mechanisms include reduced beta-adrenergic receptor signal transduction and defective cardiac electromechanical coupling.
  • No specific therapy can be recommended but it should be supportive and directed against the heart failure.
  • Transjugular intrahepatic portosystemic shunt insertion and liver transplantation affect cardiac function in portal hypertensive patients and cause stress to the cirrhotic heart, with a risk of perioperative heart failure.
  • Future research should focus on beneficial effects of treatment on cardiac function and mortality.
  • [MeSH-major] Heart Diseases / complications. Heart Diseases / etiology. Liver Diseases / complications. Liver Diseases / etiology
  • [MeSH-minor] Animals. Disease Models, Animal. Electrocardiography. Heart Failure / complications. Heart Failure / physiopathology. Hemodynamics. Humans. Liver Cirrhosis / etiology. Liver Cirrhosis / physiopathology

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210113.001).
  • [ISSN] 1747-4132
  • [Journal-full-title] Expert review of gastroenterology & hepatology
  • [ISO-abbreviation] Expert Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 139
  •  go-up   go-down


51. Chattipakorn N, Settakorn J, Petsophonsakul P, Suwannahoi P, Mahakranukrauh P, Srichairatanakool S, Chattipakorn SC: Cardiac mortality is associated with low levels of omega-3 and omega-6 fatty acids in the heart of cadavers with a history of coronary heart disease. Nutr Res; 2009 Oct;29(10):696-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac mortality is associated with low levels of omega-3 and omega-6 fatty acids in the heart of cadavers with a history of coronary heart disease.
  • The benefits of omega-3 (ie, eicosapentaenoic acid and docosahexaenoic acid [DHA]) and omega-6 (ie, linoleic acid and arachidonic acid [AA]) fatty acids on reducing cardiac mortality are still debated.
  • In this study, we tested the hypothesis that high levels of omega-3 and omega-6 fatty acids in heart tissues are associated with low cardiac mortality in Thai cadavers.
  • The cause of death, history of coronary heart disease (CHD), and fish consumption habits were obtained from death certificates, cadaver medical record profiles, and a questionnaire to a person who lived with the subject before death.
  • In each cadaver, biopsies of cardiac tissues were taken from the interventricular septum for measurement of fatty acid.
  • The frequency of fish consumption was directly associated with omega-3 and omega-6 fatty acids in heart tissues (P < .01).
  • History of CHD and cause of death (cardiac vs noncardiac) were not significantly associated with levels of omega-3 or omega-6 fatty acids.
  • However, in cadavers with a history of CHD, high levels of omega-3 and omega-6, particularly DHA and AA, were associated with low cardiac mortality (P < .05).
  • Fish consumption is associated with levels of omega-3 and omega-6 fatty acids in heart tissues.
  • Although omega-3 and omega-6 fatty acids are not associated with cardiac mortality in the overall studied population, their low levels (especially DHA and AA) in heart tissues are associated with high cardiac mortality in cadavers with a history of CHD.

  • Genetic Alliance. consumer health - Heart Disease.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917448.001).
  • [ISSN] 1879-0739
  • [Journal-full-title] Nutrition research (New York, N.Y.)
  • [ISO-abbreviation] Nutr Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


52. Gott M, Barnes S, Parker C, Payne S, Seamark D, Gariballa S, Small N: Dying trajectories in heart failure. Palliat Med; 2007 Mar;21(2):95-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dying trajectories in heart failure.
  • OBJECTIVES: To explore dying trajectories in heart failure.
  • PARTICIPANTS: A total of 27 heart failure patients, >60 years of age, who completed questionnaires for at least five time-points before death.
  • RESULTS: No 'typical' dying trajectory could be identified, and only a minority of patients conformed to the theoretical trajectory of dying in heart failure.
  • CONCLUSIONS: This study provides the first prospective data regarding physical decline prior to death in heart failure.
  • Findings challenge current efforts to plan and deliver palliative care services on the basis of the theoretical heart failure dying trajectory.
  • [MeSH-major] Heart Failure / physiopathology. Palliative Care / statistics & numerical data. Terminally Ill / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344257.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Cay S, Cagirci G, Atak R, Balbay Y, Demir AD, Aydogdu S: Heart rate profile during exercise in patients with early repolarization. Chin Med J (Engl); 2010 Sep;123(17):2305-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart rate profile during exercise in patients with early repolarization.
  • BACKGROUND: Both early repolarization and altered heart rate profile are associated with sudden death.
  • In this study, we aimed to demonstrate an association between early repolarization and heart rate profile during exercise.
  • Resting heart rate, maximum heart rate, heart rate increment and decrement were analyzed.
  • RESULTS: Both groups were comparable for baseline characteristics including resting heart rate.
  • Maximum heart rate, heart rate increment and heart rate decrement of the subjects in early repolarization group had significantly decreased maximum heart rate, heart rate increment and heart rate decrement compared to control group (all P < 0.05).
  • The lower heart rate increment (< 106 beats/min) and heart rate decrement (< 95 beats/min) were significantly associated with the presence of early repolarization.
  • After adjustment for age and sex, the multiple-adjusted OR of the risk of presence of early repolarization was 2.98 (95%CI 1.21-7.34) (P = 0.018) and 7.73 (95%CI 2.84-21.03) (P < 0.001) for the lower heart rate increment and heart rate decrement compared to higher levels, respectively.
  • CONCLUSIONS: Subjects with early repolarization have altered heart rate profile during exercise compared to control subjects.
  • [MeSH-major] Electrocardiography. Exercise / physiology. Heart Rate
  • [MeSH-minor] Adult. Autonomic Nervous System / physiology. Case-Control Studies. Exercise Test. Female. Heart Conduction System / physiopathology. Humans. Male

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21034539.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] China
  •  go-up   go-down


54. Fukuta H, Ohte N, Brucks S, Carr JJ, Little WC: Contribution of right-sided heart enlargement to cardiomegaly on chest roentgenogram in diastolic and systolic heart failure. Am J Cardiol; 2007 Jan 1;99(1):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of right-sided heart enlargement to cardiomegaly on chest roentgenogram in diastolic and systolic heart failure.
  • We investigated the contribution of a dilated right-sided heart to roentgenographic cardiomegaly in patients with heart failure (HF) and a normal ejection fraction (EF; diastolic HF) and those with HF and a decreased EF (systolic HF).
  • We compared the cardiothoracic ratio (CTR) on upright chest roentgenograms and major- and minor-axis dimensions of the 4 cardiac chambers on echocardiograms in patients with HF and a normal EF (> or =0.50, n = 35) and those with a decreased EF (<0.50, n = 37) and examined the correlation between the CTR and cardiac chamber dimensions.
  • Left-side cardiac chamber dimensions were substantially smaller in patients with a normal EF than in those with a decreased EF (left ventricular minor-axis dimension, 4.4 +/- 0.7 vs 5.8 +/- 0.8 cm, p <0.001).
  • In contrast, right-side cardiac chamber dimensions were generally similar between groups.
  • The CTR correlated with major-axis dimensions of the right ventricle and right atrium (p <0.01 for the 2 comparisons), but not with the left-side cardiac chamber dimensions (all p values >0.05).
  • In conclusion, the CTR predominantly reflects right- rather than left-sided heart size in patients with HF.
  • Right-sided heart size is similar between patients with normal and decreased EF values.
  • [MeSH-major] Heart Failure / physiopathology. Hypertrophy, Right Ventricular / physiopathology. Stroke Volume

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196464.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Batchelder K, Mayosi BM: Pentoxifylline for heart failure: a systematic review. S Afr Med J; 2005 Mar;95(3):171-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentoxifylline for heart failure: a systematic review.
  • BACKGROUND: Recent trials have indicated a beneficial effect of pentoxifylline on measures of inflammation and markers of cardiac dysfunction in people with heart failure.
  • However, it is uncertain whether pentoxifylline should be used routinely in the management of heart failure.
  • OBJECTIVE: To determine the effectiveness of pentoxifylline in heart failure.
  • METHODS: We searched MEDLINE (1 January 1966 - 20 November 2004), the Cochrane Controlled Trials Register (issue 4, 2004), and reference lists of related papers, for randomised controlled trials of pentoxifylline in the treatment of heart failure.
  • The following outcome measures were evaluated: (i) New York Heart Association (NYHA) functional class;.
  • The four studies tested the use of pentoxifylline versus placebo in patients with heart failure of varying aetiology (idiopathic dilated cardiomyopathy, 3 studies; ischaemic cardiomyopathy, 1 study).
  • NYHA functional class) and cardiac function (i.e.
  • The beneficial effect on symptoms of heart failure and cardiac function was seen in all grades of severity of heart failure and in patients with ischaemic and idiopathic dilated cardiomyopathy.
  • INTERPRETATION: Pentoxifylline may have a beneficial effect on NYHA functional class, ejection fraction and mortality in heart failure, but published trials are too small to provide conclusive evidence.
  • There is a need for large, placebo-controlled trials of pentoxifylline in heart failure, involving a diverse group of patients with regard to cause and severity of heart failure.
  • [MeSH-major] Heart Failure / drug therapy. Pentoxifylline / therapeutic use

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832667.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Vasodilator Agents; SD6QCT3TSU / Pentoxifylline
  • [Number-of-references] 13
  •  go-up   go-down


56. Coletta AP, Clark AL, Cleland JG: Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA. Eur J Heart Fail; 2009 Feb;11(2):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA.
  • This article provides information and a commentary on trials relevant to the pathophysiology, prevention, and treatment of heart failure presented at the Heart Failure Society of America and the American Heart Association meetings in 2008.
  • Unpublished reports should be considered as preliminary, as analyses may change in the final publication. (i) SADHART-CHF showed no difference in outcome for heart failure patients with depression treated with sertraline compared with placebo. (ii) A controlled release carvedilol formulation showed similar LV haemodynamic effects to the standard carvedilol formulation in the COMPARE study. (iii) A post hoc analysis of the MOMENTUM study suggested that patients with less severe heart failure may be more likely to benefit from a continuous aortic flow augmentation device. (iv) A thyroid hormone analogue was poorly tolerated in patients with heart failure. (v) HF-ACTION showed that exercise training is safe and offers modest clinical benefits in patients with heart failure. (vi) Irbesartan failed to improve outcomes in patients with preserved ejection fraction in the I-PRESERVE study. (vii) A phase II study of beta-interferon administration in patients with dilated cardiomyopathy showed encouraging results. (viii) The BACH study showed that mid-regional pro-adrenomedullin was more accurate than BNP or NT-proBNP at predicting outcome at 90 days in patients with acute heart failure. (ix) A secondary analysis from ATHENA showed a reduction in cardiovascular hospitalizations and strokes for patients with atrial fibrillation receiving dronedarone compared with placebo.
  • [MeSH-major] Heart Failure / therapy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Heart Fail. 2008 Jun;10(6):614-20 [18502685.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1351-8 [18171701.001]
  • [Cites] Eur J Heart Fail. 2008 Jul;10(7):714-21 [18565789.001]
  • [Cites] Am Heart J. 2008 Sep;156(3):437-44 [18760123.001]
  • [Cites] Circulation. 2008 Sep 16;118(12):1241-9 [18765394.001]
  • [Cites] Eur J Heart Fail. 2008 Sep;10(9):917-20 [18678526.001]
  • [Cites] Eur J Heart Fail. 2008 Oct;10(10):933-89 [18826876.001]
  • [Cites] Eur J Heart Fail. 2008 Dec;10(12):1264-7 [19008149.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23):2456-67 [19001508.001]
  • [Cites] J Am Coll Cardiol. 2009 Feb 17;53(7):608-11 [19215836.001]
  • [Cites] Am Heart J. 2002 Jul;144(1):23-30 [12094184.001]
  • [Cites] Thyroid. 2002 Jun;12(6):527-33 [12165118.001]
  • [Cites] JAMA. 2002 Aug 14;288(6):701-9 [12169073.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):14-21 [12853194.001]
  • [Cites] Chin Med J (Engl). 2003 Nov;116(11):1697-700 [14642140.001]
  • [Cites] BMJ. 2004 Jan 24;328(7433):189 [14729656.001]
  • [Cites] Am J Med. 2004 May 15;116(10):693-706 [15121496.001]
  • [Cites] Am J Cardiol. 1994 Feb 15;73(5):374-8 [8109552.001]
  • [Cites] Am J Cardiol. 2006 Oct 2;98(7A):53L-59L [17023233.001]
  • [Cites] J Am Coll Cardiol. 2006 Oct 17;48(8):1527-37 [17045884.001]
  • [Cites] Am Heart J. 2007 Feb;153(2):201-11 [17239677.001]
  • [Cites] Am Heart J. 2007 Jul;154(1):102-8 [17584561.001]
  • [Cites] Eur J Heart Fail. 2007 Dec;9(12):1212-22 [18029292.001]
  • [Cites] Br J Clin Pharmacol. 2007 Dec;64(6):785-91 [17662087.001]
  • [Cites] Eur J Heart Fail. 2008 Feb;10(2):149-56 [18279770.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2678-87 [18565860.001]
  • (PMID = 19168521.001).
  • [ISSN] 1388-9842
  • [Journal-full-title] European journal of heart failure
  • [ISO-abbreviation] Eur. J. Heart Fail.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2639420
  •  go-up   go-down


57. Mahony L, Sleeper LA, Anderson PA, Gersony WM, McCrindle BW, Minich LL, Newburger JW, Saul JP, Vetter VL, Pearson GD, Pediatric Heart Network Investigators: The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol; 2006 Mar-Apr;27(2):191-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease.
  • In response to this concern, the National Heart, Lung, and Blood Institute established the Pediatric Heart Disease Clinical Research Network (PHN) in 2001.
  • Design and conduct of complex, multicenter studies in children with congenital and acquired heart disease must address numerous challenges, including identification of an appropriate clinically relevant primary endpoint, lack of preliminary data on which to base sample size calculations, and recruitment of an adequate number of subjects.
  • [MeSH-major] Clinical Trials as Topic / methods. Heart Defects, Congenital. Heart Diseases. Research Design

  • Genetic Alliance. consumer health - Heart Disease.
  • Genetic Alliance. consumer health - Congenital Heart Defects.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Aug 25;282(8):771-8 [10463714.001]
  • [Cites] Control Clin Trials. 2000 Apr;21(2):103-14 [10715508.001]
  • [Cites] J Am Coll Cardiol. 2004 Dec 21;44(12):2285-92 [15607388.001]
  • [Cites] J Pediatr. 2001 Jan;138(1):76-80 [11148516.001]
  • [Cites] JAMA. 2003 Mar 12;289(10 ):1278-87 [12633190.001]
  • [Cites] Semin Perinatol. 2003 Aug;27(4):343-50 [14510325.001]
  • [Cites] Lancet. 2004 Aug 28-Sep 3;364(9436):803-11 [15337409.001]
  • [Cites] Am Heart J. 2001 Aug;142(2):229-32 [11479459.001]
  • [Cites] Circulation. 2002 Aug 27;106(9):1037-42 [12196324.001]
  • [Cites] Semin Perinatol. 2003 Aug;27(4):264-80 [14510317.001]
  • [Cites] Semin Perinatol. 2003 Jun;27(3):253-60 [12889593.001]
  • [Cites] Circulation. 2002 Aug 6;106(6):746-51 [12163438.001]
  • [Cites] J Card Fail. 2001 Jun;7(2):176-82 [11420770.001]
  • (PMID = 16261271.001).
  • [ISSN] 0172-0643
  • [Journal-full-title] Pediatric cardiology
  • [ISO-abbreviation] Pediatr Cardiol
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL068269; United States / NHLBI NIH HHS / HL / U01 HL068270; United States / NHLBI NIH HHS / HL / U01 HL068279; United States / NHLBI NIH HHS / HL / U01 HL068281; United States / NHLBI NIH HHS / HL / U01 HL068285; United States / NHLBI NIH HHS / HL / U01 HL068288; United States / NHLBI NIH HHS / HL / U01 HL068290; United States / NHLBI NIH HHS / HL / U01 HL068292
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


58. Altundag MB, Ertas G, Ucer AR, Durmus S, Abanuz H, Calikoğlu T, Ozbagi K, Demirkasimoglu A, Kaya B, Bakkal BH, Altundag K: Brain metastasis of cardiac myxoma: case report and review of the literature. J Neurooncol; 2005 Nov;75(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis of cardiac myxoma: case report and review of the literature.
  • Cardiac myxoma is the most common benign heart tumor.
  • Cardiac myxoma can be a sporadic lesion (93% of cases) and usually occurs in women over 30 years.
  • Complete surgical removal of the myxoma and its cardiac attachment is usually curative.
  • The frequency of recurrences in cardiac myxomas varies between 3% for sporadic cases and 22% for cases of Carney complex.
  • Recurrence has been related to incomplete excision, multifocality, and embolism of tumor fragments.
  • We report a case with multiple brain metastases presumably due to tumor embolization from previously operated cardiac myxoma.
  • [MeSH-major] Brain Neoplasms / secondary. Heart Neoplasms / pathology. Myxoma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2003 May;123(5):1379-85 [12740251.001]
  • [Cites] Surg Neurol. 1979 Jun;11(6):461-9 [483155.001]
  • [Cites] Chest. 1995 Mar;107(3):674-9 [7874936.001]
  • [Cites] Int J Cardiol. 2004 Apr;94(2-3):325-6 [15094003.001]
  • [Cites] Radiographics. 2002 May-Jun;22(3):673-89 [12006696.001]
  • [Cites] Am J Surg Pathol. 1980 Aug;4(4):391-9 [7425205.001]
  • [Cites] J Thorac Cardiovasc Surg. 1986 Mar;91(3):389-96 [3951243.001]
  • [Cites] N Engl J Med. 1995 Dec 14;333(24):1610-7 [7477198.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Feb;89(2):298-303 [3968914.001]
  • [Cites] Int J Cardiol. 2004 Sep;96(3):471-3 [15301902.001]
  • [Cites] Neuroradiology. 1987;29(2):218 [3587605.001]
  • [Cites] Am Heart J. 2000 Jul;140(1):134-8 [10874274.001]
  • [Cites] Ann Thorac Surg. 1998 Nov;66(5):1791-2 [9875791.001]
  • [Cites] Am J Cardiol. 2002 Sep 1;90(5):563-5 [12208428.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] Cardiology. 1991;78(1):72-7 [2021969.001]
  • [Cites] Chest. 1978 Oct;74(4):451-2 [699660.001]
  • [Cites] Heart. 2001 Feb;85(2):218-22 [11156679.001]
  • [Cites] Thorac Cardiovasc Surg. 2004 Oct;52(5):302-4 [15470613.001]
  • [Cites] Circ J. 2004 Dec;68(12):1230-2 [15564714.001]
  • [Cites] Neurochirurgie. 1987;33(6):487-9 [3444488.001]
  • [Cites] Am J Cardiol. 1968 Mar;21(3):315-27 [5688975.001]
  • [Cites] Tex Heart Inst J. 2001;28(1):3-7 [11330738.001]
  • [Cites] Am J Surg Pathol. 1994 Jan;18(1):107-11 [8279623.001]
  • [Cites] Am J Clin Pathol. 1993 Dec;100(6):671-80 [8249916.001]
  • [Cites] J Formos Med Assoc. 2001 Jan;100(1):63-5 [11265265.001]
  • [Cites] Am Heart J. 1986 Feb;111(2):409-13 [3946183.001]
  • [Cites] J Neurosurg. 1990 Feb;72 (2):295-8 [2404090.001]
  • [Cites] Am J Med Genet. 1998 Nov 2;80(2):183-5 [9805140.001]
  • [Cites] Br Heart J. 1992 Jan;67(1):89-91 [1531423.001]
  • [Cites] Int J Cardiol. 1994 Jun 15;45(2):144-6 [7960255.001]
  • [Cites] Arch Neurol. 1970 Dec;23(6):558-67 [5478277.001]
  • [Cites] Am Heart J. 1990 Mar;119(3 Pt 1):679-80 [2309613.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):185-90 [3122705.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Dec;22(6):971-7 [12467822.001]
  • [Cites] Surg Neurol. 1992 May;37(5):374-9 [1631764.001]
  • (PMID = 16132507.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


59. Misfeld M, Sievers HH: Heart valve macro- and microstructure. Philos Trans R Soc Lond B Biol Sci; 2007 Aug 29;362(1484):1421-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart valve macro- and microstructure.
  • Each heart valve is composed of different structures of which each one has its own histological profile.
  • Although the aortic and the pulmonary valves as well as the mitral and the tricuspid valves show similarities in their architecture, they are individually designed to ensure optimal function with regard to their role in the cardiac cycle.
  • In this article, we systematically describe the structural elements of the four heart valves by different anatomical, light- and electron-microscopic techniques that have been presented.
  • Without the demand of completeness, we describe main structural features that are in our opinion of importance in understanding heart valve performance.
  • These features will also have important implications in the treatment of heart valve disease.
  • In addition, understanding heart valve macro- and microstructure may also be of benefit in heart valve engineering techniques.
  • [MeSH-major] Heart Valves / anatomy & histology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardioscience. 1992 Dec;3(4):241-4 [1477291.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Jan;107(1):162-70 [8283879.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):H319-28 [8304514.001]
  • [Cites] J Heart Valve Dis. 1994 Sep;3(5):491-6 [8000582.001]
  • [Cites] Anat Rec. 1995 Mar;241(3):391-400 [7755179.001]
  • [Cites] Ann Thorac Surg. 1995 Aug;60(2 Suppl):S391-4 [7646194.001]
  • [Cites] Anat Rec. 1995 Nov;243(3):367-75 [8579256.001]
  • [Cites] Jpn Circ J. 1996 Jan;60(1):62-6 [8648885.001]
  • [Cites] Circulation. 1996 Aug 1;94(3):368-75 [8759078.001]
  • [Cites] J Heart Valve Dis. 1996 Sep;5(5):464-71 [8894984.001]
  • [Cites] J Cell Physiol. 1996 Dec;169(3):439-47 [8952693.001]
  • [Cites] J Heart Valve Dis. 1996 Nov;5 Suppl 3:S249-57 [8953449.001]
  • [Cites] Ann Thorac Surg. 1999 Sep;68(3 Suppl):S37-43 [10505990.001]
  • [Cites] Ann Thorac Surg. 1999 Sep;68(3):949-53; discussion 953-4 [10509990.001]
  • [Cites] Ann Thorac Surg. 1991 Sep;52(3):640-6 [1898167.001]
  • [Cites] J Heart Valve Dis. 1999 Nov;8(6):697-701 [10616250.001]
  • [Cites] J Heart Valve Dis. 2000 Jan;9(1):1-7; discussion 7-8 [10678369.001]
  • [Cites] Heart. 2000 Apr;83(4):376-80 [10722531.001]
  • [Cites] J Heart Valve Dis. 2000 May;9(3):445-53 [10888104.001]
  • [Cites] Heart. 2000 Dec;84(6):670-3 [11083753.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Feb;123(2):333-40 [11828294.001]
  • [Cites] Circulation. 2002 Aug 6;106(6):711-7 [12163432.001]
  • [Cites] Ann Thorac Surg. 2003 Mar;75(3):830-4 [12645702.001]
  • [Cites] J Biomech. 2003 Aug;36(8):1125-33 [12831738.001]
  • [Cites] Circulation. 2004 Mar 2;109(8):942-50 [14993146.001]
  • [Cites] J Biomech Eng. 2004 Apr;126(2):244-51 [15179855.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Sep;26(3):634-9 [15302062.001]
  • [Cites] Saudi Med J. 2004 Sep;25(9):1176-85 [15448762.001]
  • [Cites] Verh Dtsch Ges Kreislaufforsch. 1965;31:1-15 [5332461.001]
  • [Cites] Circ Res. 1967 Jul;21(1):9-15 [6028860.001]
  • [Cites] Lancet. 1967 Nov 4;2(7523):956-8 [4167516.001]
  • [Cites] Nature. 1968 Jan 6;217(5123):86-7 [5635642.001]
  • [Cites] Z Rheumaforsch. 1966 Feb;25(1):10-8 [5995900.001]
  • [Cites] Nature. 1968 Sep 7;219(5158):1059-61 [5673366.001]
  • [Cites] Isr J Med Sci. 1969 Jul-Aug;5(4):862-6 [5820535.001]
  • [Cites] Circ Res. 1972 Sep;31(3):417-30 [5057021.001]
  • [Cites] Am J Anat. 1973 Nov;138(3):347-69 [4748717.001]
  • [Cites] J Thorac Cardiovasc Surg. 1974 May;67(5):792-804 [4823314.001]
  • [Cites] Trans Am Soc Artif Intern Organs. 1974;20 B:437-48 [4450296.001]
  • [Cites] Am J Physiol. 1976 May;230(5):1366-73 [1275079.001]
  • [Cites] J Thorac Cardiovasc Surg. 1976 Sep;72(3):413-7 [957758.001]
  • [Cites] Arch Pathol Lab Med. 1977 May;101(5):236-8 [576796.001]
  • [Cites] Acta Anat (Basel). 1977;98(2):199-205 [871080.001]
  • [Cites] Br Heart J. 1977 Sep;39(9):1006-11 [907764.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Jan;75(1):121-30 [339002.001]
  • [Cites] Am J Physiol. 1978 Feb;234(2):H146-51 [623315.001]
  • [Cites] Experientia. 1978 Dec 15;34(12):1636-8 [729742.001]
  • [Cites] J Biomech. 1980;13(2):97-104 [7364784.001]
  • [Cites] Circ Res. 1980 Nov;47(5):792-800 [7418136.001]
  • [Cites] Circulation. 1981 Jul;64(1):113-20 [7237707.001]
  • [Cites] Jpn Heart J. 1983 Jul;24(4):539-48 [6645048.001]
  • [Cites] Anat Embryol (Berl). 1981;161(3):329-40 [7187826.001]
  • [Cites] Am J Cardiol. 1985 Feb 1;55(4):454-61 [3155899.001]
  • [Cites] Circ Res. 1986 Sep;59(3):310-20 [3769149.001]
  • [Cites] Cardiovasc Res. 1986 Oct;20(10):760-7 [3791342.001]
  • [Cites] World Health Organ Tech Rep Ser. 1988;764:1-58 [3131967.001]
  • [Cites] JAMA. 1990 May 2;263(17):2335-40 [2109105.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Mar;113(3):453-61 [9081089.001]
  • [Cites] N Engl J Med. 1997 Aug 28;337(9):581-8 [9271479.001]
  • [Cites] Clin Anat. 1997;10(5):297-302 [9283725.001]
  • [Cites] Clin Anat. 1997;10(5):307-12 [9283727.001]
  • [Cites] Circulation. 1997 Nov 18;96(10):3403-8 [9396434.001]
  • [Cites] J Am Coll Cardiol. 1998 May;31(6):1420-5 [9581744.001]
  • [Cites] J Biomech. 1998 Feb;31(2):115-23 [9593204.001]
  • [Cites] J Anat. 1998 May;192 ( Pt 4):573-81 [9723984.001]
  • [Cites] Okajimas Folia Anat Jpn. 1999 Mar;75(6):323-8 [10217951.001]
  • [Cites] N Engl J Med. 1999 Jul 15;341(3):142-7 [10403851.001]
  • [Cites] J Heart Valve Dis. 1999 Jul;8(4):407-15 [10461241.001]
  • [Cites] J Surg Res. 1994 Jul;57(1):1-21 [8041124.001]
  • [Cites] J Heart Valve Dis. 1999 Mar;8(2):162-6 [10224576.001]
  • (PMID = 17581807.001).
  • [ISSN] 0962-8436
  • [Journal-full-title] Philosophical transactions of the Royal Society of London. Series B, Biological sciences
  • [ISO-abbreviation] Philos. Trans. R. Soc. Lond., B, Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 83
  • [Other-IDs] NLM/ PMC2440405
  •  go-up   go-down


60. Zachman DK, Chicco AJ, McCune SA, Murphy RC, Moore RL, Sparagna GC: The role of calcium-independent phospholipase A2 in cardiolipin remodeling in the spontaneously hypertensive heart failure rat heart. J Lipid Res; 2010 Mar;51(3):525-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of calcium-independent phospholipase A2 in cardiolipin remodeling in the spontaneously hypertensive heart failure rat heart.
  • In the mammalian heart, the functional form of CL is tetralinoleoyl CL [(18:2)(4)CL].
  • A decrease in (18:2)(4)CL content, which is believed to negatively impact mitochondrial energetics, occurs in heart failure (HF) and other mitochondrial diseases.
  • These results suggest that CL remodeling occurs in a step-wise manner, that compromised 18:2 incorporation contributes to a reduction in (18:2)(4)CL in the failing rat heart, and that mitochondrial iPLA(2) plays a role in the remodeling of CL's acyl composition.
  • [MeSH-major] Cardiolipins / chemistry. Cardiolipins / metabolism. Heart Failure / metabolism. Myocardium / metabolism. Phospholipases A2, Calcium-Independent / metabolism
  • [MeSH-minor] Animals. Enzyme Inhibitors / pharmacology. Female. Heart / drug effects. Heart / physiopathology. Myocytes, Cardiac / drug effects. Myocytes, Cardiac / metabolism. Myocytes, Cardiac / pathology. Phosphatidylglycerols / metabolism. Rats. Rats, Inbred SHR. Stress, Physiological. Time Factors. Tissue Survival / drug effects

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Mol Med. 1998 Jan;1(1):33-41 [9852196.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:175-89 [10331081.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C33-44 [16899548.001]
  • [Cites] Biochemistry. 2007 May 29;46(21):6417-28 [17487985.001]
  • [Cites] J Lipid Res. 2007 Jul;48(7):1559-70 [17426348.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34611-22 [17923475.001]
  • [Cites] Hypertension. 2008 Apr;51(4):1096-102 [18259016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2337-41 [19164547.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1791(4):321-5 [19416646.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1791(4):314-20 [19416660.001]
  • [Cites] J Lipid Res. 2009 Aug;50(8):1600-8 [19001357.001]
  • [Cites] Biochemistry. 1999 Nov 9;38(45):14966-72 [10555978.001]
  • [Cites] Br J Nutr. 2000 Mar;83 Suppl 1:S59-66 [10889793.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):378-82 [11118295.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):38061-7 [11500520.001]
  • [Cites] Biochem J. 2002 Feb 15;362(Pt 1):23-32 [11829736.001]
  • [Cites] Ann Thorac Surg. 2002 Apr;73(4):1216-21 [11996266.001]
  • [Cites] Ann Neurol. 2002 May;51(5):634-7 [12112112.001]
  • [Cites] J Mol Cell Cardiol. 2006 Jan;40(1):56-63 [16324710.001]
  • [Cites] Prog Lipid Res. 2006 Mar;45(2):91-101 [16442164.001]
  • [Cites] Lipids Health Dis. 2006;5:2 [16430781.001]
  • [Cites] FEBS Lett. 2006 May 29;580(13):3059-64 [16678169.001]
  • [Cites] Free Radic Biol Med. 2006 Jul 15;41(2):238-46 [16814104.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32807-14 [12089145.001]
  • [Cites] FEBS Lett. 2002 Sep 25;528(1-3):35-9 [12297275.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Nov;283(5):H1775-84 [12384454.001]
  • [Cites] Free Radic Biol Med. 1999 Jul;27(1-2):42-50 [10443918.001]
  • [Cites] Biochemistry (Mosc). 2005 Feb;70(2):154-8 [15807653.001]
  • [Cites] J Lipid Res. 2005 Jun;46(6):1196-204 [15772420.001]
  • [Cites] Annu Rev Nutr. 2005;25:317-40 [16011470.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2030-8 [15994855.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H304-11 [16143657.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1763(5-6):542-8 [16730811.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):22275-88 [16728389.001]
  • [Cites] FEBS Lett. 2006 Oct 9;580(23):5450-5 [16973164.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):103-9 [16939411.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39217-24 [17082194.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43553-6 [12364341.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):12716-21 [12569106.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44683-90 [12952946.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2202-8 [14656982.001]
  • [Cites] J Am Coll Cardiol. 2003 Dec 3;42(11):1994-9 [14662265.001]
  • [Cites] Biochem Cell Biol. 2004 Feb;82(1):99-112 [15052331.001]
  • [Cites] Am J Med Genet A. 2004 May 1;126A(4):349-54 [15098233.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31727-34 [15152008.001]
  • [Cites] Biochim Biophys Acta. 1972 Mar 23;260(3):507-13 [4556770.001]
  • [Cites] Biochim Biophys Acta. 1977 Aug 1;468(3):389-410 [195609.001]
  • [Cites] Am J Physiol. 1982 Sep;243(3):C184-90 [7114249.001]
  • [Cites] Biochem J. 1986 Nov 15;240(1):247-52 [3827844.001]
  • [Cites] J Biol Chem. 1989 Feb 15;264(5):2945-50 [2644274.001]
  • [Cites] Biochem J. 1990 Dec 15;272(3):589-95 [2268287.001]
  • [Cites] J Biol Chem. 1991 Apr 15;266(11):7227-32 [2016324.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Aug 14;186(3):1384-90 [1510668.001]
  • [Cites] FEBS Lett. 1993 Sep 6;330(1):71-6 [8370463.001]
  • [Cites] Biochem J. 1994 Jan 1;297 ( Pt 1):201-8 [8280100.001]
  • [Cites] Am Heart J. 1995 Oct;130(4):806-11 [7572590.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 1996 Jan;51(1):B54-9 [8548501.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3902-7 [8632987.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6758-65 [8636097.001]
  • [Cites] J Biol Chem. 1996 Oct 18;271(42):25810-6 [8824210.001]
  • [Cites] Mol Cell Biochem. 1996 Jun 21;159(2):139-48 [8858564.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31937-41 [8943239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7 [9113986.001]
  • [Cites] Science. 1997 May 2;276(5313):800-6 [9115206.001]
  • [Cites] Biochim Biophys Acta. 1997 Sep 4;1348(1-2):207-13 [9370335.001]
  • [Cites] Mol Cell Biochem. 1997 Nov;176(1-2):179-89 [9406160.001]
  • (PMID = 19741254.001).
  • [ISSN] 1539-7262
  • [Journal-full-title] Journal of lipid research
  • [ISO-abbreviation] J. Lipid Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiolipins; 0 / Enzyme Inhibitors; 0 / Phosphatidylglycerols; 0 / tetralinoleoylcardiolipin; EC 3.1.1.4 / Phospholipases A2, Calcium-Independent
  • [Other-IDs] NLM/ PMC2817582
  •  go-up   go-down


61. Soran OZ, Feldman AM, Piña IL, Lamas GA, Kelsey SF, Selzer F, Pilotte J, Lave JR: Cost of medical services in older patients with heart failure: those receiving enhanced monitoring using a computer-based telephonic monitoring system compared with those in usual care: the Heart Failure Home Care trial. J Card Fail; 2010 Nov;16(11):859-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost of medical services in older patients with heart failure: those receiving enhanced monitoring using a computer-based telephonic monitoring system compared with those in usual care: the Heart Failure Home Care trial.
  • BACKGROUND: Prior studies suggest that disease management programs may be effective in improving clinical and economic outcomes in patients with heart failure.
  • This study was designed to assess the impact of a home-based disease management program, the Alere DayLink HF Monitoring System (HFMS), on the clinical and economic outcomes of Medicare beneficiaries recently hospitalized for heart failure who received the care from a community-based primary care practitioner.
  • METHODS AND RESULTS: The Heart Failure Home Care trial was a multicenter, randomized, controlled trial of sophisticated, monitoring of heart failure patients with an interactive program versus standard heart failure care with enhanced patient education and follow-up (SC) in Medicare-eligible patients.
  • The study endpoints included cardiovascular death or rehospitalization for heart failure, length of hospital stay, total patient cost, and cost to Medicare at 6 months of enrollment.
  • There were no significant statistical differences between the groups in regards to 6-month cardiac mortality, rehospitalizations for heart failure, or length of hospital stay.
  • [MeSH-major] Heart Failure / economics. Heart Failure / therapy. Telemetry

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21055649.001).
  • [ISSN] 1532-8414
  • [Journal-full-title] Journal of cardiac failure
  • [ISO-abbreviation] J. Card. Fail.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors
  •  go-up   go-down


62. Köhler F, Schierbaum C, Konertz W, Schneider M, Kern H, Int E, Tael K, Siigur U, Kleinfeld K, Bühlmeyer K, Fotuhi P, Winter SF: Partnership for the heart. German-Estonian health project for the treatment of congenital heart defects in Estonia. Health Policy; 2005 Aug;73(2):151-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partnership for the heart. German-Estonian health project for the treatment of congenital heart defects in Estonia.
  • Congenital heart defects (CHD) occur in 8 per 1000 live births.
  • Based on the experience gained in this process, a plan for improvement of care of Estonian patients with CHD was developed and implemented in the German-Estonian project, "Partnership for the Heart".
  • During the project 15 Estonian patients underwent cardiac surgery and/or catheter interventions performed by a joint team of German and Estonian specialists.
  • Key techniques of cardiac surgery are now being employed in Estonia without outside support, indicating the success of the training program and the long-term improvements to cardiac health care in Estonia.
  • The structure of "Partnership for the Heart" and the modified self-sufficiency model of medical care have not only produced results for Estonia but can be taken as a template for future bilateral health projects with other transition countries and for other fields of medical specialisation, and thus might aid a European health policy.
  • [MeSH-major] Heart Defects, Congenital / therapy. International Cooperation


63. Bakas T, Pressler SJ, Johnson EA, Nauser JA, Shaneyfelt T: Family caregiving in heart failure. Nurs Res; 2006 May-Jun;55(3):180-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family caregiving in heart failure.
  • BACKGROUND: Little is known about the experiences of family caregivers of patients with heart failure, despite the fact that these patients have disabling symptoms and diminished functioning that could lead to caregiver stress.
  • OBJECTIVES: Based on a caregiver model, the aims of this study were to (a) examine relationships among age, perceived control over managing heart problems, perceived difficulty with tasks, perceived outcomes, and perceived mental and general health among caregivers of persons with heart failure;.
  • (b) describe caregivers' perceptions of control over managing heart problems; and (c) describe the tasks and outcomes perceived as being most difficult and negative by caregivers.
  • METHODS: A sample of 21 family caregivers of patients with heart failure completed the study questionnaires.
  • The patients with heart failure were male veterans with New York Heart Association (NYHA) Class II, III, or IV.
  • Caregivers' perceived control over managing heart problems was related moderately to poorer perceived mental health.
  • [MeSH-major] Caregivers / psychology. Heart Failure / psychology

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708042.001).
  • [ISSN] 0029-6562
  • [Journal-full-title] Nursing research
  • [ISO-abbreviation] Nurs Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


64. Jayle C, Franco S, Bris L, Lefort G, Corbi P: [Multiple myxomata: about one case]. Arch Mal Coeur Vaiss; 2007 Oct;100(10):878-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the primitive cardiac tumours, myxoma is the most common.
  • This benign tumour is sometimes described in the context of Carney's syndrome, in which cardiac myxoma, cutaneous myxoma, lentigo and pigmentary nevus cutaneous lesions, endocrine disorders, and testicular, thyroid and hypophyseal tumours are associated.
  • The cardiac myxomata observed are multiple, recurrent, and involve the four cardiac chambers, with a peak incidence at 25 years of age.
  • [MeSH-major] Chromosomes, Human, Pair 7. Heart Neoplasms / genetics. Myxoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18033020.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


65. Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM, CLARICOR Trial Group: Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology; 2008;111(4):280-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease.
  • OBJECTIVES: We have reported increased 2.6-year mortality in clarithromycin- versus placebo-exposed stable coronary heart disease patients, but meta-analysis of randomized trials in coronary heart disease patients showed no significant effect of antibiotics on mortality.
  • RESULTS: We randomized 4,372 patients with stable coronary heart disease to clarithromycin 500 mg (n = 2,172) or placebo (n = 2,200) once daily for 2 weeks.
  • Addition of our data to that of other randomized trials on antibiotics for patients with coronary heart disease versus placebo/no intervention (17 trials, 25,271 patients, 1,877 deaths) showed a significantly increased relative risk of death from antibiotics of 1.10 (1.01-1.20) without heterogeneity.
  • CONCLUSIONS: Our results stress the necessity to consider carefully the strength of the indication before administering antibiotics to patients with coronary heart disease.

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • [Cites] Circulation. 2001 Jan 23;103(3):351-6 [11157684.001]
  • [Cites] Lancet. 2001 Jun 30;357(9274):2085-9 [11445102.001]
  • [Cites] Ann Intern Med. 2001 Dec 4;135(11):982-9 [11730399.001]
  • [Cites] Circulation. 2002 Mar 19;105(11):1298-303 [11901039.001]
  • [Cites] Circulation. 2002 Apr 2;105(13):1555-60 [11927522.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Circulation. 2003 Mar 11;107(9):1228-30 [12628937.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):607-9 [12828043.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Jul;10(4):525-8 [12853380.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):733-8 [14962945.001]
  • [Cites] Am Heart J. 2004 Jul;148(1):72-9 [15215794.001]
  • [Cites] Int Immunopharmacol. 2004 Sep;4(9):1201-7 [15251115.001]
  • [Cites] Int J Antimicrob Agents. 2004 Sep;24(3):247-53 [15325428.001]
  • [Cites] J Exp Med. 2004 Oct 4;200(7):905-16 [15452181.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):408-12 [7823387.001]
  • [Cites] Circulation. 1997 Jul 15;96(2):404-7 [9244203.001]
  • [Cites] Lancet. 1997 Aug 9;350(9075):404-7 [9259655.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1858-9 [9652673.001]
  • [Cites] Lancet. 1998 Aug 22;352(9128):609-13 [9746022.001]
  • [Cites] Rom J Intern Med. 2003;41(3):237-46 [15526507.001]
  • [Cites] Clin Infect Dis. 2005 Feb 1;40(3):358-65 [15668857.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1637-45 [15843666.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1646-54 [15843667.001]
  • [Cites] JAMA. 2005 Jun 1;293(21):2641-7 [15928286.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):218-28 [16014596.001]
  • [Cites] BMJ. 2006 Jan 7;332(7532):22-7 [16339220.001]
  • [Cites] JAMA. 2007 Feb 28;297(8):842-57 [17327526.001]
  • [Cites] BMJ. 2007 Apr 14;334(7597):786 [17403713.001]
  • [CommentIn] Cardiology. 2008;111(4):277-9 [18451645.001]
  • (PMID = 18451646.001).
  • [ISSN] 1421-9751
  • [Journal-full-title] Cardiology
  • [ISO-abbreviation] Cardiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; H1250JIK0A / Clarithromycin
  • [Other-IDs] NLM/ PMC2820332
  • [Investigator] Jensen P; Pipper C; Mieritz J; Thuesen L; Larsen H; Nielsen P; Hildebrandt M; Bommersholdt M; Kristensen L; Petersen JV; Hughes P; Hansen B; Frydendahl N; Hødholdt B; Juliussen K; Hansen M; Nillson K; Salas N; Thygesen K; Kjekshus J; Haunsø S; Steffensen R; Sørensen TI
  •  go-up   go-down


66. Michael Felker G: Diuretic management in heart failure. Congest Heart Fail; 2010 Jul;16 Suppl 1:S68-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diuretic management in heart failure.
  • Many of the primary clinical manifestations of heart failure are due to fluid retention and congestion, and therefore treatments targeting congestion play a central role in heart failure management.
  • Diuretic therapy remains the cornerstone of congestion treatment, and diuretics are prescribed to the majority of heart failure patients.
  • Some observational data have suggested that diuretics may actually be harmful in heart failure, potentially contributing to worsening renal function, neurohormonal activation, and even heart failure progression.
  • This review describes the mechanism of action of available diuretic classes, reviews their clinical use based on current guidelines, and briefly discusses evolving alternatives to diuretic therapy in the management of congestion in heart failure patients.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Diuretics / therapeutic use. Heart Failure / drug therapy

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653715.001).
  • [ISSN] 1751-7133
  • [Journal-full-title] Congestive heart failure (Greenwich, Conn.)
  • [ISO-abbreviation] Congest Heart Fail
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Diuretics; 0 / Sodium Chloride Symporter Inhibitors; 0 / Sodium Potassium Chloride Symporter Inhibitors
  •  go-up   go-down


67. Elkayam U, Bitar F: Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial. Am J Cardiol; 2005 Oct 10;96(7B):37i-43i
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
  • This combination leads to a significant improvement in cardiac function, with a concomitant reduction in right and left ventricular filling pressures and augmentation of cardiac output.
  • Based on this hemodynamic profile, the Vasodilator Heart Failure Trial (V-HeFT) was designed to examine the effect of this drug combination on the outcome of patients with congestive heart failure (CHF).
  • This observation led to the design of the African American Heart Failure Trial (A-HeFT), which confirmed the benefit of these drugs in combination in African American patients with CHF.
  • [MeSH-major] African Americans. Heart Failure / drug therapy. Heart Failure / ethnology. Hydralazine / administration & dosage. Isosorbide Dinitrate / administration & dosage
  • [MeSH-minor] Animals. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Follow-Up Studies. Heart Function Tests. Hemodynamics / drug effects. Humans. Randomized Controlled Trials as Topic. Rats. Rats, Sprague-Dawley. Risk Assessment. Severity of Illness Index. Stroke Volume / drug effects. Survival Rate. Treatment Outcome


68. Ozgun M, Hoffmeier A, Quante M, Fischbach R, Heindel W, Botnar R, Maintz D: [Whole-heart coronary MR angiography -- initial results]. Rofo; 2006 May;178(5):500-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Whole-heart coronary MR angiography -- initial results].
  • [Transliterated title] Whole-Heart-MR-Koronarangiographie -- erste Ergebnisse.
  • MATERIALS AND METHODS: Six healthy volunteers and 15 patients with known CAD were examined with a navigator gated and corrected (NAV) free-breathing 3D steady-state free precession sequence covering the whole heart (WH-MRA) (TR = 5.4, TE = 2.7, SENSE factor = 2, 160 slices, 0.75 mm reconstructed slice thickness, in-plane resolution = 0.99 x 0.99 mm(2), scan time 14 min [50 % NAV efficiency]) and a vessel targeted 3D SSFP MRA sequence (t-MRA) (TR = 5.6 ms, TE = 2.8 ms, 20 slices of 1.5 mm reconstructed slice thickness, in-plane resolution = 0.99 x 0.99 mm(2), scan time = 7 min [50 % NAV efficiency]).
  • [MeSH-major] Coronary Disease / diagnosis. Coronary Vessels / anatomy & histology. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardiac Catheterization. Coronary Angiography. Data Interpretation, Statistical. Female. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612789.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Mulder P, Thuillez C: Heart rate slowing for myocardial dysfunction/heart failure. Adv Cardiol; 2006;43:97-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart rate slowing for myocardial dysfunction/heart failure.
  • Heart failure is a major health problem, and is one of the few cardiovascular diseases that increased its prevalence over the last decade.
  • Increased heart rate, generally observed in patients with heart failure, is involved in the deterioration of cardiac pump function.
  • However, the effects of 'pure' heart rate reduction on the progression of heart failure are unknown.
  • In a rat model of heart failure, ivabradine, a blocker of I(f) channels reduces dose-dependently heart rate without modification of blood pressure.
  • This heart rate reduction is associated with an improvement in cardiac function.
  • After chronic administration, this improvement of cardiac function persists after ivabradine withdrawal, revealing an improvement in intrinsic myocardial function.
  • This beneficial effect could be explained by direct effects of heart rate reduction induced by ivabradine, i.e. improved myocardial oxygen supply to demand ratio, and/or myocardial tissular effects induced by chronic decrease in heart rate such, i.e. decreased extracellular collagen accumulation, increased myocardial microcirculation.
  • In conclusion, 'pure' chronic heart rate reduction can be beneficial in heart failure.
  • [MeSH-major] Benzazepines / pharmacology. Cardiotonic Agents / pharmacology. Heart Failure / drug therapy. Heart Rate / drug effects
  • [MeSH-minor] Animals. Cardiac Output / drug effects. Heart Conduction System / drug effects. Heart Conduction System / physiopathology. Humans. Ion Channels / drug effects. Myocardium / chemistry. Rats. Sinoatrial Node / drug effects

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936475.001).
  • [ISSN] 0065-2326
  • [Journal-full-title] Advances in cardiology
  • [ISO-abbreviation] Adv Cardiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Benzazepines; 0 / Cardiotonic Agents; 0 / Ion Channels; 3H48L0LPZQ / ivabradine
  • [Number-of-references] 29
  •  go-up   go-down


70. Jiménez Navarro MF, Díez Martínez J, Delgado Jiménez JF, Crespo Leiro MG: [Heart failure in 2005]. Rev Esp Cardiol; 2006;59 Suppl 1:55-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Heart failure in 2005].
  • This article is a review of developments reported in the field of heart failure in the last year.
  • It covers advances in epidemiology, pathophysiology and therapy, including cardiac resynchronization therapy and heart transplantation.
  • Today, management of heart failure is complex.
  • The increasing prevalence of heart failure means that continuing research is mandatory.
  • [MeSH-major] Heart Failure
  • [MeSH-minor] Heart Transplantation. Humans

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540021.001).
  • [ISSN] 1579-2242
  • [Journal-full-title] Revista española de cardiología
  • [ISO-abbreviation] Rev Esp Cardiol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 91
  •  go-up   go-down


71. Yin W, Gallocher S, Pinchuk L, Schoephoerster RT, Jesty J, Bluestein D: Flow-induced platelet activation in a St. Jude mechanical heart valve, a trileaflet polymeric heart valve, and a St. Jude tissue valve. Artif Organs; 2005 Oct;29(10):826-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow-induced platelet activation in a St. Jude mechanical heart valve, a trileaflet polymeric heart valve, and a St. Jude tissue valve.
  • Polymer heart valves have been under investigation since the 1960s, but their success has been hampered by an overall lack of durability mainly due to calcification of the leaflets and a relatively high rate of thromboembolic complications.
  • A new polymer (Quatromer) trileaflet design was tested for its thrombogenic potential and was compared to that of existing prosthetic heart valves routinely implanted in patients: a St. Jude Medical bileaflet mechanical heart valve (MHV) and a St. Jude porcine bioprosthetic tissue valve.
  • [MeSH-major] Bioprosthesis. Coated Materials, Biocompatible. Heart Valve Prosthesis. Platelet Activation. Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185345.001).
  • [ISSN] 0160-564X
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible
  •  go-up   go-down


72. Young LE, Molzahn A, Starzomski R, Budz B: Families and heart transplantation: reversing the trajectory of end stage heart disease. Can J Cardiovasc Nurs; 2010;20(2):6-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Families and heart transplantation: reversing the trajectory of end stage heart disease.
  • Family caregiving is central in the heart transplant (HT) process.
  • FINDINGS: Our interpretations suggest that family caregiving contributes to "reversing the downward trajectory" of end stage heart disease.
  • [MeSH-major] Adaptation, Psychological. Attitude to Health. Caregivers / psychology. Family / psychology. Heart Failure. Heart Transplantation / psychology


73. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR: Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation; 2009 Feb 24;119(7):969-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.
  • BACKGROUND: In the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial, 1520 patients with advanced heart failure were assigned in a 1:2:2 ratio to optimal pharmacological therapy or optimal pharmacological therapy plus cardiac resynchronization therapy (CRT-P) or CRT with defibrillator (CRT-D).
  • Compared with optimal pharmacological therapy, CRT-P and CRT-D were associated with a 21% and 25% reduction in all-cause, 34% and 37% reduction in cardiac, and 44% and 41% reduction in heart failure hospital admissions per patient-year of follow-up, respectively.
  • The reduction in hospitalization rate for heart failure in the CRT groups appeared within days of randomization and remained sustained.
  • CONCLUSIONS: Use of CRT with or without a defibrillator in advanced heart failure patients was associated with marked reductions in all-cause, cardiac, and heart failure hospitalization rates in an analysis that accounted for the competing risk of mortality and unequal follow-up time.
  • [MeSH-major] Cardiac Pacing, Artificial. Defibrillators, Implantable. Heart Failure / therapy. Hospitalization / statistics & numerical data


74. Bruneau BG: Chromatin remodeling in heart development. Curr Opin Genet Dev; 2010 Oct;20(5):505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromatin remodeling in heart development.
  • Heart development is a complex process that relies on networks of interacting transcription factors.
  • Mutations in genes encoding some of these transcription factors result in many inherited congenital heart defects and point to the importance of these networks.
  • Chromatin remodeling complexes are intimately associated with these transcriptional networks, adding an additional layer of complexity and fine-tuning to the regulation of heart development.
  • Understanding these relationships will be crucial to understand fundamental concepts in tissue-specific gene regulation in organogenesis, in unraveling the mechanisms of congenital heart disease, as well as providing new avenues for reprogramming new cardiomyocytes for heart repair.
  • [MeSH-major] Chromatin Assembly and Disassembly. Gene Expression Regulation, Developmental. Heart / embryology. Heart Defects, Congenital / genetics

  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20702085.001).
  • [ISSN] 1879-0380
  • [Journal-full-title] Current opinion in genetics & development
  • [ISO-abbreviation] Curr. Opin. Genet. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Histones; 0 / Transcription Factors
  •  go-up   go-down


75. Hsu RB: Heart transplantation in patients with end-stage heart failure and cardiac ascites. Circ J; 2007 Nov;71(11):1744-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart transplantation in patients with end-stage heart failure and cardiac ascites.
  • BACKGROUND: Clinical outcome of heart transplantation in patients with heart failure and ascites has not been reported.
  • Here, the clinical outcome of heart transplantation in patients with heart failure and ascites is evaluated.
  • METHODS AND RESULTS: Between 1989 and 2005, 45 patients with heart failure and ascites underwent an orthotopic heart transplantation.
  • Causes of heart failure included congenital heart disease in 4 patients (9%), dilated cardiomyopathy in 21 patients (47%), rheumatic heart disease in 7 patients (16%), coronary artery disease in 10 patients (22%), and others.
  • Twenty of the 45 patients (44%) had undergone a previous cardiac operation.
  • CONCLUSIONS: Heart transplantation in patients with heart failure and ascites was associated with high hospital mortality and morbidity.
  • [MeSH-major] Ascites / surgery. Heart Failure / surgery. Heart Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965495.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


76. Yu K, Liu Y, Wang H, Hu S, Long C: Epidemiological and pathological characteristics of cardiac tumors: a clinical study of 242 cases. Interact Cardiovasc Thorac Surg; 2007 Oct;6(5):636-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological and pathological characteristics of cardiac tumors: a clinical study of 242 cases.
  • The purpose of this study was to review the current clinical experience and pathological characteristics of cardiac tumors.
  • We retrospectively reviewed 33,108 consecutive cases of cardiac operations performed at our institution from October 1996 to March 2005.
  • There were 242 cases confirmed histologically as cardiac tumors.
  • Among them, 234 patients were diagnosed with primary heart tumors, revealing a prevalence of 0.71% among the corresponding period cardiac operations.
  • Of primary cardiac tumors, the incidence of benign neoplasm was much higher than malignant masses (90.6% vs. 9.4%, P<0.01).
  • The most common benign cardiac tumor was myxoma (86.8%).
  • Mesenchymoma and angiosarcoma were the most common primary malignant cardiac tumors.
  • The prevalence rates of cardiac tumors were quite different among age groups.
  • Benign non-myxoma tumors are more likely to occur in the ventricular (64.3%).
  • All the secondary cardiac tumors were located in the right side of the heart.
  • This study, using a relatively large sample, reveals the clinical incidences and pathological characteristics of various cardiac tumors in the Chinese population.
  • [MeSH-major] Asian Continental Ancestry Group / statistics & numerical data. Heart Neoplasms. Hemangiosarcoma. Lipoma. Mesenchymoma. Myxoma. Rhabdomyoma
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. China / epidemiology. Female. Humans. Incidence. Infant. Male. Middle Aged. Neoplasm Metastasis. Prevalence. Retrospective Studies. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670730.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Roberts F, Ryan GJ: The safety of metformin in heart failure. Ann Pharmacother; 2007 Apr;41(4):642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The safety of metformin in heart failure.
  • OBJECTIVE: To examine the evidence regarding the safety of metformin in heart failure.
  • Search terms included metformin, heart failure, lactic acidosis, clinical trials, and insulin resistance.
  • STUDY SELECTION AND DATA EXTRACTION: Published studies and case reports that evaluated the causal link between metformin and lactic acidosis in patients with heart failure were selected for review.
  • DATA SYNTHESIS: There were no case reports of patients who had metformin-associated lactic acidosis when heart failure was the only contraindication.
  • Two large retrospective studies showed that metformin does not increase the risk of lactic acidosis in patients with heart failure.
  • A reduction in mortality rates in metformin users with New York Heart Association Class III and IV heart failure was observed in one small (N = 94) prospective trial.
  • CONCLUSIONS: Results from 3 trials suggest that metformin may be safe to use in heart failure.
  • Until then, use of metformin in heart failure patients should not be recommended routinely.
  • If it is used in patients with heart failure, they should be monitored closely for signs of lactic acidosis.
  • [MeSH-major] Acidosis, Lactic / chemically induced. Heart Failure / drug therapy. Hypoglycemic Agents / therapeutic use. Metformin / therapeutic use

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374622.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 9100L32L2N / Metformin
  • [Number-of-references] 23
  •  go-up   go-down


78. Yeh JL, Hsu JH, Dai ZK, Liou SF, Chen IJ, Wu JR: Increased circulating big endothelin-1, endothelin-1 and atrial natriuretic peptide in infants and children with heart failure secondary to congenital heart disease. Int J Cardiol; 2005 Sep 15;104(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased circulating big endothelin-1, endothelin-1 and atrial natriuretic peptide in infants and children with heart failure secondary to congenital heart disease.
  • In order to characterize the changes of five neurohormones in pediatric patients with varying degrees of congestive heart failure (CHF) secondary to congenital heart disease (CHD), we measured plasma neurohormone levels by using radioimmunoassay or high-performance liquid chromatography in 81 subjects including 13 normal children and 68 pediatric patients with CHD.
  • There was also a highly significant stepwise increase in big ET-1, atrial natriuretic peptide and norepinephrine according to the severity of heart failure.
  • Our results suggest that increased circulating neurohormonal activity in CHD relates to the presence and clinical severity of heart failure in children.
  • [MeSH-major] Atrial Natriuretic Factor / blood. Endothelin-1 / blood. Heart Defects, Congenital / blood. Heart Defects, Congenital / complications. Heart Failure / blood. Heart Failure / etiology


79. Kumar D, Carvalho P, Antunes M, Henriques J, Sá e Melo A, Schmidt R, Habetha J: Third heart sound detection using wavelet transform-simplicity filter. Conf Proc IEEE Eng Med Biol Soc; 2007;2007:1277-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Third heart sound detection using wavelet transform-simplicity filter.
  • Heart failure and heart valvar diseases are chronic heart disorders which are potentially diagnosed using heart sound characteristics.
  • Heart sound components S1 and S2 exhibit significant characteristics for valvar dysfunction while pathological S3 sound is a prominent sign for heart failure in elderly people.
  • In this paper, a new automatic detection method of the S3 heart sound is proposed.
  • The method is build upon wavelet transform-simplicity filter which separates S1, S2 and S3 sounds from background noise enabling heart sound segmentation even in the presence of heart murmurs or noise sources.
  • The algorithm uses physiologically inspired criteria to assess the presence of S3 heart sound components and to perform their segmentation.
  • Heart sound samples recorded from children as well as from elderly patients with heart failure were used to test the method.
  • [MeSH-major] Algorithms. Diagnosis, Computer-Assisted / methods. Heart Auscultation / methods. Heart Failure / diagnosis. Heart Sounds. Signal Processing, Computer-Assisted. Sound Spectrography / methods

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18002196.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Issa VS, Amaral AF, Cruz FD, Ayub-Ferreira SM, Guimarães GV, Chizzola PR, Souza GE, Bocchi EA: Glycemia and prognosis of patients with chronic heart failure--subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial. Am Heart J; 2010 Jan;159(1):90-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycemia and prognosis of patients with chronic heart failure--subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial.
  • BACKGROUND: Heart failure and diabetes often occur simultaneously in patients, but the prognostic value of glycemia in chronic heart failure is debatable.
  • We evaluated the role of glycemia on prognosis of heart failure.
  • METHODS: Outpatients with chronic heart failure from the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial were grouped according to the presence of diabetes and level of glycemia.
  • All-cause mortality/heart transplantation and unplanned hospital admission were evaluated.
  • During follow-up (3.6 +/- 2.2 years), 27 (5.9%) patients were submitted to heart transplantation and 202 (44.2%) died; survival was similar in patients with and without diabetes mellitus.
  • CONCLUSION: We report on an inverse association between glycemia and mortality in outpatients with chronic heart failure.
  • These results point to a new pathophysiologic understanding of the interactions between diabetes mellitus, hyperglycemia, and heart disease.
  • [MeSH-major] Blood Glucose / analysis. Cause of Death. Diabetes Mellitus / mortality. Heart Failure / mortality. Hyperglycemia / mortality

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20102872.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00505050
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


81. Hua LP, Brown CA, Hains SJ, Godwin M, Parlow JL: Effects of low-intensity exercise conditioning on blood pressure, heart rate, and autonomic modulation of heart rate in men and women with hypertension. Biol Res Nurs; 2009 Oct;11(2):129-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of low-intensity exercise conditioning on blood pressure, heart rate, and autonomic modulation of heart rate in men and women with hypertension.
  • Untreated hypertension increases cardiovascular risk 2-fold to 3-fold, leading to serious cardiovascular problems that include left ventricular hypertrophy, stroke, ischemic heart disease, myocardial infarction, vascular disease, renal disease, and death.
  • The purpose of this pretest-posttest study was to quantify the effects of a 12-week home-based low-intensity exercise conditioning (walking) program in hypertensive men and women on systolic and diastolic blood pressure, heart rate, and autonomic modulation of heart rate.
  • Electrocardiographic heart rate and R-R interval data and beat-by-beat arterial blood pressure data were collected continuously for 10 min with participants in the supine and standing postures and during low-intensity steady-state exercise.
  • [MeSH-major] Blood Pressure. Exercise Therapy. Heart Rate. Hypertension / therapy. Walking

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150992.001).
  • [ISSN] 1552-4175
  • [Journal-full-title] Biological research for nursing
  • [ISO-abbreviation] Biol Res Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Zhu H, Rothermel BA, Hill JA: Autophagy in load-induced heart disease. Methods Enzymol; 2009;453:343-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autophagy in load-induced heart disease.
  • The heart is a highly plastic organ capable of remodeling in response to changes in physiological or pathological demand.
  • When workload increases, the heart compensates through hypertrophic growth of individual cardiomyocytes to increase cardiac output.
  • However, sustained stress, such as occurs with hypertension or following myocardial infarction, triggers changes in sarcomeric protein composition and energy metabolism, loss of cardiomyocytes, ventricular dilation, reduced pump function, and ultimately heart failure.
  • This latter fact stems largely from the recent emergence of tools to probe molecular mechanisms governing cardiac plasticity and to define the role of autophagic flux in the context of heart disease.
  • In this chapter, we briefly review prominent mouse models useful in the study of load-induced heart disease and standard techniques used to assess whether a molecular or cellular event is adaptive or maladaptive.
  • We then outline methods available for monitoring autophagic activity in the heart, providing detailed protocols for several techniques unique to working with heart and other striated muscles.

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2002 Dec;14(6):727-33 [12473346.001]
  • [Cites] Autophagy. 2008 Oct;4(7):932-5 [18769158.001]
  • [Cites] Circulation. 2003 Feb 25;107(7):984-91 [12600911.001]
  • [Cites] Circ Res. 2003 Apr 18;92(7):715-24 [12649263.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1101-11 [14699058.001]
  • [Cites] Circulation. 2004 Apr 6;109(13):1580-9 [15066961.001]
  • [Cites] J Am Coll Cardiol. 2004 Jun 16;43(12):2191-9 [15193679.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Recent Adv Stud Cardiac Struct Metab. 1976 May 26-29;12:453-63 [1032000.001]
  • [Cites] Am J Pathol. 1980 Feb;98(2):425-44 [7355988.001]
  • [Cites] J Mol Cell Cardiol. 1980 Nov;12(11):1175-89 [7441766.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1983;43(3):287-307 [6137901.001]
  • [Cites] J Mol Cell Cardiol. 1987 Dec;19(12):1179-84 [3443985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8277-81 [1832775.001]
  • [Cites] JAMA. 1996 May 22-29;275(20):1557-62 [8622246.001]
  • [Cites] Science. 2004 Nov 5;306(5698):990-5 [15528435.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:657-87 [15822192.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):672-6 [10604474.001]
  • [Cites] J Mol Cell Cardiol. 2000 Jan;32(1):161-75 [10652200.001]
  • [Cites] Circulation. 2000 Jun 20;101(24):2863-9 [10859294.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5720-8 [11060023.001]
  • [Cites] EMBO Rep. 2001 Apr;2(4):330-5 [11306555.001]
  • [Cites] Cardiovasc Res. 2001 Aug 1;51(2):304-12 [11470470.001]
  • [Cites] Jpn Circ J. 2001 Nov;65(11):965-8 [11716248.001]
  • [Cites] J Histochem Cytochem. 2001 Dec;49(12):1565-72 [11724904.001]
  • [Cites] Physiol Genomics. 2005 Sep 21;23(1):18-27 [16033866.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Aug;7(8):589-600 [16936699.001]
  • [Cites] Nature. 2006 Oct 19;443(7113):780-6 [17051204.001]
  • [Cites] Circ Res. 2007 Mar 30;100(6):914-22 [17332429.001]
  • [Cites] Nat Med. 2007 May;13(5):619-24 [17450150.001]
  • [Cites] Methods Mol Biol. 2007;366:321-30 [17568133.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1782-93 [17607355.001]
  • [Cites] J Biol Chem. 2007 Aug 17;282(33):24131-45 [17580304.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):632-4 [17786025.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7 [17712358.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2861-73 [18006683.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] Circulation. 2008 Jan 29;117(4):e25-146 [18086926.001]
  • [Cites] Annu Rev Pathol. 2008;3:427-55 [18039129.001]
  • [Cites] N Engl J Med. 2008 Mar 27;358(13):1370-80 [18367740.001]
  • [Cites] Circulation. 2008 Jun 17;117(24):3070-8 [18541737.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9745-50 [18621691.001]
  • [Cites] Annu Rev Physiol. 2003;65:45-79 [12524460.001]
  • (PMID = 19216915.001).
  • [ISSN] 1557-7988
  • [Journal-full-title] Methods in enzymology
  • [ISO-abbreviation] Meth. Enzymol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL097768; United States / NHLBI NIH HHS / HL / HL-080144; United States / NHLBI NIH HHS / HL / R01 HL075173; United States / NHLBI NIH HHS / HL / R01 HL072016; United States / NHLBI NIH HHS / HL / R01 HL080144; United States / NHLBI NIH HHS / HL / HL-075173; United States / NHLBI NIH HHS / HL / HL-72016
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lamp1 protein, mouse; 0 / Lysosome-Associated Membrane Glycoproteins; 0 / MAP1LC3 protein, mouse; 0 / Microtubule-Associated Proteins; EC 3.4.23.5 / Cathepsin D
  • [Other-IDs] NLM/ NIHMS125108; NLM/ PMC2784933
  •  go-up   go-down


83. Katircibasi MT, Canatar T, Kocum HT, Erol T, Tekin G, Demircan S, Tekin A, Sezgin AT, Baltali M, Muderrisoglu H: Decreased heart rate recovery in patients with heart failure: effect of fluvastatin therapy. Int Heart J; 2005 Sep;46(5):845-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased heart rate recovery in patients with heart failure: effect of fluvastatin therapy.
  • Heart rate recovery is the difference in heart rate at peak exercise and at a specific time interval following the onset of recovery.
  • Attenuated heart rate recovery is an independent predictor of mortality in patients with a history of coronary artery disease.
  • The aim of the present study was to evaluate the effect of a statin on heart rate recovery, particularly in patients with ischemic heart failure and hyperlipidemia.
  • Twenty-nine consecutive hyperlipidemic, stable coronary artery disease patients with heart failure and 19 healthy subjects were enrolled.
  • Heart rate recovery values at the 1st and 3rd minutes and lipid profiles of the patients were evaluated at baseline and following 3 months of treatment with fluvastatin.
  • Compared with healthy subjects, the heart rate recovery values were significantly lower in the heart failure patients in both the 1st and 3rd minutes, respectively (31 +/- 6 versus 19 +/- 7, P < 0.0001; 66 +/- 7 versus 47 +/- 8, P < 0.0001).
  • Heart rate recovery in the 1st and 3rd minutes increased from 19 +/- 7 to 24 +/- 9 and 47 +/- 8 to 57 +/- 11, respectively, following treatment (P < 0.001, P < 0.001).
  • The results revealed an improvement in heart rate recovery in heart failure patients by fluvastatin treatment.
  • [MeSH-major] Coronary Artery Disease / physiopathology. Fatty Acids, Monounsaturated / therapeutic use. Heart Failure / drug therapy. Heart Failure / physiopathology. Heart Rate / physiology. Indoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272775.001).
  • [ISSN] 1349-2365
  • [Journal-full-title] International heart journal
  • [ISO-abbreviation] Int Heart J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Fatty Acids, Monounsaturated; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Indoles; 0 / Lipids; 4L066368AS / fluvastatin
  •  go-up   go-down


84. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC: Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation; 2010 Oct 5;122(14):1387-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
  • Little is known about GDF-15 as a biomarker in patients with heart failure.
  • METHODS AND RESULTS: The circulating concentration of GDF-15 was measured at baseline (n=1734) and at 12 months (n=1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT).
  • Higher levels were associated with features of worse heart failure and biomarkers of neurohormonal activation, inflammation, myocyte injury, and renal dysfunction.
  • CONCLUSIONS: GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure.
  • [MeSH-major] Growth Differentiation Factor 15 / blood. Heart Failure / physiopathology. Tetrazoles / therapeutic use. Valine / analogs & derivatives

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. VALSARTAN .
  • Hazardous Substances Data Bank. L-Valine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855664.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Biomarkers; 0 / Growth Differentiation Factor 15; 0 / Placebos; 0 / Tetrazoles; 80M03YXJ7I / Valsartan; HG18B9YRS7 / Valine
  •  go-up   go-down


85. Abozguia K, Shivu GN, Ahmed I, Phan TT, Frenneaux MP: The heart metabolism: pathophysiological aspects in ischaemia and heart failure. Curr Pharm Des; 2009;15(8):827-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The heart metabolism: pathophysiological aspects in ischaemia and heart failure.
  • The morbidity and mortality of coronary heart disease and of heart failure remain unacceptably high despite major advances in their management.
  • The main focus of treatment has been revascularisation for ischaemic heart disease and neuro-humoral modification for heart failure.
  • Recently, there has been a great deal of interest in the role of disturbances in cardiac energetics and myocardial metabolism in the pathophysiology of both ischaemic heart disease and heart failure and of therapeutic potential of metabolic modulation.
  • This review focuses on the key changes that occur to the metabolism of the heart in ischaemia and in heart failure and its effects on cardiac energetics.
  • [MeSH-major] Heart Failure / metabolism. Heart Failure / physiopathology. Myocardial Ischemia / metabolism. Myocardial Ischemia / physiopathology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. GLUCOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275646.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fatty Acids, Nonesterified; 0 / Vasodilator Agents; 8L70Q75FXE / Adenosine Triphosphate; EC 2.3.1.21 / Carnitine O-Palmitoyltransferase; IY9XDZ35W2 / Glucose
  • [Number-of-references] 100
  •  go-up   go-down


86. Nakajima Y: Second lineage of heart forming region provides new understanding of conotruncal heart defects. Congenit Anom (Kyoto); 2010 Mar;50(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second lineage of heart forming region provides new understanding of conotruncal heart defects.
  • Abnormal heart development causes various congenital heart defects.
  • Recent cardiovascular biology studies have elucidated the morphological mechanisms involved in normal and abnormal heart development.
  • The primitive heart tube originates from the lateral-most part of the heart forming mesoderm and mainly gives rise to the left ventricle.
  • Then, during the cardiac looping, the outflow tract is elongated by the addition of cardiogenic cells from the both pharyngeal and splanchnic mesoderm (corresponding to anterior and secondary heart field, respectively), which originate from the mediocaudal region of the heart forming mesoderm and are later located anteriorly (rostrally) to the dorsal region of the heart tube.
  • Therefore, the heart progenitors that contribute to the outflow tract region are distinct from those that form the left ventricle.
  • The knowledge that there are two different lineages of heart progenitors in the four-chambered heart provides new understanding of the morphological and molecular etiology of conotruncal heart defects.
  • [MeSH-major] Cell Lineage. Heart / embryology. Heart Defects, Congenital / embryology
  • [MeSH-minor] Animals. Gene Expression Regulation, Developmental. Heart Ventricles / embryology. Humans. Infant, Newborn. Mesoderm / cytology. Transposition of Great Vessels / embryology

  • Genetic Alliance. consumer health - Heart Defects.
  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20050864.001).
  • [ISSN] 1741-4520
  • [Journal-full-title] Congenital anomalies
  • [ISO-abbreviation] Congenit Anom (Kyoto)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 86
  •  go-up   go-down


87. Dang NC, Topkara VK, Mercando M, Kay J, Kruger KH, Aboodi MS, Oz MC, Naka Y: Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant; 2006 Jan;25(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure.
  • BACKGROUND: Right heart failure (RHF) is not an infrequent complication of left ventricular assist device (LVAD) implantation.
  • This study details one center's experience with RHF in chronic congestive heart failure (CHF) patients.
  • Acute heart failure patients requiring LVADs were excluded to eliminate the impact of confounding non-cardiac factors.
  • [MeSH-major] Heart Failure / surgery. Heart-Assist Devices / adverse effects. Ventricular Dysfunction, Right / etiology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399523.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Berger R, Huelsmann M, Strecker K, Moertl D, Moser P, Bojic A, Pacher R: Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur J Clin Invest; 2005 Jan;35(1):24-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure.
  • BACKGROUND: This study tested various neurohormones for prediction of heart failure death (death owing to progressive deterioration of ventricular function; HFD).
  • DESIGN: BNP, the N-terminal fragment of BNP (N-BNP), and of the atrial natriuretic peptide (N-ANP) and big endothelin levels were obtained from 452 patients with a left ventricular ejection fraction </= 35%.
  • RESULTS: Two hundred and ninety-eight patients survived without heart transplantation, 65 patients underwent heart transplantation and 89 patients died (SD 44 patients, HFD 31 patients, other causes 14 patients).
  • [MeSH-major] Atrial Natriuretic Factor / blood. Death, Sudden / etiology. Heart Failure / metabolism. Natriuretic Peptide, Brain / blood. Protein Precursors / blood

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638816.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / N-terminal proatrial natriuretic peptide; 0 / Protein Precursors; 114471-18-0 / Natriuretic Peptide, Brain; 85637-73-6 / Atrial Natriuretic Factor
  •  go-up   go-down


89. Shenoy M, Chapman CB, Nawaz MZ, Sweitzer NK: Diagnosis and management of stage a heart failure. Congest Heart Fail; 2006 May-Jun;12(3):146-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of stage a heart failure.
  • Reduction of the monetary and societal costs of the heart failure epidemic can best be achieved by prevention of new heart failure cases.
  • To effectively prevent heart failure, patients at risk must be identified and treated.
  • The American College of Cardiology/American Heart Association Guidelines for Evaluation and Management of Chronic Heart Failure in the Adult define the stage A heart failure patient as one with identified risk factors for heart failure, particularly coronary heart disease, hypertension, and diabetes, but no evidence of cardiovascular damage.
  • The authors also discuss data demonstrating that risk factor modification can reduce heart failure incidence.
  • Given the size of the population at risk, through increased awareness of heart failure risk and aggressive treatment, health care providers can critically impact this public health concern.
  • [MeSH-major] Heart Failure / prevention & control

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760700.001).
  • [ISSN] 1527-5299
  • [Journal-full-title] Congestive heart failure (Greenwich, Conn.)
  • [ISO-abbreviation] Congest Heart Fail
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


90. Zielasek J: [Mind and heart--heart and mind]. Med Klin (Munich); 2006 Mar 22;101 Suppl 1:66-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mind and heart--heart and mind].
  • [Transliterated title] Psyche und Herz--Herz und Psyche.
  • In common parlance, the close relationship between the heart and the mind is well known.
  • Epidemiologic investigations of the last 20 years have put this relationship on an empirically confirmed basis: patients with heart disease, especially coronary artery disease, suffer from major depression at a rate exceeding chance alone.
  • The reasons are still unknown, but current hypotheses focus on the influence of depression on endothelial function, blood coagulation, cardiac arrhythmias, inflammatory reactions, and lifestyle factors.
  • Depression in patients with heart disease must be treated equally vigorously as in patients without heart disease.
  • It is important for the clinician to consider major and minor depression in the differential diagnosis of psychiatric and somatic symptoms in patients with heart disease, to diagnose depression without delay, and promptly initiate an appropriate therapy according to current treatment guidelines.
  • [MeSH-minor] Antidepressive Agents / therapeutic use. Depressive Disorder, Major / epidemiology. Depressive Disorder, Major / psychology. Depressive Disorder, Major / therapy. Humans. Psychotherapy. Risk Factors. Serotonin Uptake Inhibitors / therapeutic use. Statistics as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16802523.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Serotonin Uptake Inhibitors
  •  go-up   go-down


91. Su SW, Wang L, Celler BG, Savkin A: Heart rate control during treadmill exercise. Conf Proc IEEE Eng Med Biol Soc; 2005;3:2471-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart rate control during treadmill exercise.
  • A computer-controlled treadmill and related data collection and processing systems have been developed for the control of heart rate during treadmill exercise.
  • Minimizing deviations of heart rate from a preset profile is achieved by controlling the speed and/or the gradient of the treadmill.
  • A simple and practical heart rate measurement algorithm has been developed to robustly measure the variations of heart rate.
  • The fuzzy Proportional-Integral algorithm achieved better heart rate tracking performance.
  • Finally, a heart rate based exercising protocol was successfully implemented on the newly designed exercise system.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17282738.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Haemers P, Dujardin K: An unusual cause of carcinoid heart disease. Acta Cardiol; 2010 Dec;65(6):709-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of carcinoid heart disease.
  • Carcinoid heart disease (CHD) is a rare form of valvular heart disease characterized by right-sided heart valve dysfunction.
  • Carcinoid heart disease occurs most frequently when carcinoid tumour cells metastasize from a primary site in the gut to the liver, so that vasoactive substances produced by the tumour are able to reach the systemic circulation.
  • By contrast, in ovarian carcinoid tumours carcinoid heart disease develops in the absence of liver metastasis, because vasoactive substances can be released directly into the systemic circulation, bypassing the first-pass metabolism of the liver.
  • There are only a few case reports in the world literature of carcinoid heart disease caused by ovarian carcinoid tumour.
  • We report a case of an 85-year-old woman with carcinoid heart disease caused by a bilateral ovarian carcinoid tumour metastasized from a primary ileal site.
  • [MeSH-major] Carcinoid Heart Disease / etiology. Ileal Neoplasms / pathology. Ovarian Neoplasms / secondary


93. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, ADMIRE-HF Investigators: Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol; 2010 May 18;55(20):2212-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study.
  • OBJECTIVES: The ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study prospectively evaluated iodine-123 meta-iodobenzylguanidine ((123)I-mIBG) imaging for identifying symptomatic heart failure (HF) patients most likely to experience cardiac events.
  • METHODS: A total of 961 subjects with New York Heart Association (NYHA) functional class II/III HF and left ventricular ejection fraction (LVEF) < or =35% were studied.
  • Subjects underwent (123)I-mIBG myocardial imaging (sympathetic neuronal integrity quantified as the heart/mediastinum uptake ratio [H/M] on 4-h delayed planar images) and myocardial perfusion imaging and were then followed up for up to 2 years.
  • Time to first occurrence of NYHA functional class progression, potentially life-threatening arrhythmic event, or cardiac death was compared with H/M (either in relation to estimated lower limit of normal [1.60] or as a continuous variable) using Cox proportional hazards regression.
  • Two-year event rate was 15% for H/M > or =1.60 and 37% for H/M <1.60; hazard ratios for individual event categories were as follows: HF progression, 0.49 (p = 0.002); arrhythmic events, 0.37 (p = 0.02); and cardiac death, 0.14 (p = 0.006).
  • CONCLUSIONS: ADMIRE-HF provides prospective validation of the independent prognostic value of (123)I-mIBG scintigraphy in assessment of patients with HF. (Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease, NCT00126425; Meta-Iodobenzylguanidine [123I-mIBG] Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease, NCT00126438).
  • [MeSH-major] 3-Iodobenzylguanidine. Heart Failure / radionuclide imaging. Radiopharmaceuticals. Ventricular Dysfunction, Left / radionuclide imaging
  • [MeSH-minor] Aged. Disease Progression. Female. Heart / radionuclide imaging. Humans. Iodine Radioisotopes. Male. Mediastinum / radionuclide imaging. Middle Aged. Natriuretic Peptide, Brain / blood. Prognosis. Proportional Hazards Models. Prospective Studies. Research Design. Risk Assessment. Stroke Volume. Tomography, Emission-Computed, Single-Photon / statistics & numerical data


94. Costanzo MR: Ultrafiltration in the management of heart failure. Curr Opin Crit Care; 2008 Oct;14(5):524-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrafiltration in the management of heart failure.
  • PURPOSE OF REVIEW: Congestion causes the majority of hospitalizations for heart failure and contributes to heart failure progression and mortality.
  • Loop diuretics, however, may be associated with increased morbidity and mortality because of deleterious effects on neurohormonal activation, electrolyte balance, and cardiac and renal function.
  • Ultrafiltration, an alternative method of sodium and water removal, safely improves hemodynamics in heart failure patients.
  • RECENT FINDINGS: The Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure trial has recently shown that among 200 volume overloaded heart failure patients randomized to ultrafiltration or intravenous diuretics, 48 h weight (P = 0.001) and net fluid loss (P = 0.001) were greater in the ultrafiltration group.
  • At 90 days, the ultrafiltration group had fewer heart failure rehospitalizations/patient (P = 0.022) and patients presenting for unscheduled visits (21 vs. 44%; P = 0.009).
  • SUMMARY: In decompensated heart failure, ultrafiltration safely produces greater weight and fluid loss than intravenous diuretics, reduces rehospitalization rates for heart failure and is an effective alternative therapy.
  • [MeSH-major] Heart Failure / therapy. Ultrafiltration

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787444.001).
  • [ISSN] 1531-7072
  • [Journal-full-title] Current opinion in critical care
  • [ISO-abbreviation] Curr Opin Crit Care
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics
  • [Number-of-references] 24
  •  go-up   go-down


95. Servonnet A, Delacour H, Dehan C, Gardet V: [Heart fatty-acid binding protein (h-FABP): a new cardiac marker]. Ann Biol Clin (Paris); 2006 May-Jun;64(3):209-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Heart fatty-acid binding protein (h-FABP): a new cardiac marker].
  • [Transliterated title] Un nouveau marqueur cardiaque: la heart fatty-acid binding protein (h-FABP).
  • Heart Fatty-Acid Binding Protein (h-FABP) is a small cytosolic protein that is abundant in the heart and found at lower concentrations in muscle or in the brain. h-FABP is released into the circulation shortly after the onset of ischemia.
  • [MeSH-major] Fatty Acid-Binding Proteins / blood. Heart Diseases / blood

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698556.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / FABP3 protein, human; 0 / Fatty Acid-Binding Proteins
  • [Number-of-references] 58
  •  go-up   go-down


96. Linde C: Cardiac resynchronization therapy in mild heart failure. Europace; 2009 Nov;11 Suppl 5:v72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac resynchronization therapy in mild heart failure.
  • It has been firmly established that cardiac resynchronization therapy (CRT) reduces symptoms and improves mortality in patients with moderate-to-severe chronic heart failure [New York Heart Association (NYHA) class III-IV], despite optimal heart failure medication and with wide QRS complex on the surface electrocardiogram as evidence of ventricular dyssynchrony, but not whether such treatment is efficacious in mildly symptomatic heart failure patients.
  • Cardiac resynchronization therapy in this study induced substantial reverse remodelling over 12-18-24 months of follow-up and was linked to a significant delay in the time to first heart failure hospitalization and eventually in the time to the combined endpoint of time to first heart failure hospitalization or death.
  • The MADIT CRT designed as a morbidity-mortality study corroborated these findings with a significant reduction in heart failure events and significant reverse remodelling.
  • [MeSH-major] Cardiac Pacing, Artificial / methods. Heart Failure / therapy. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861394.001).
  • [ISSN] 1532-2092
  • [Journal-full-title] Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • [ISO-abbreviation] Europace
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. de Gevigney G, Fol S, Delahaye F: [Pathophysiology and therapeutic implications of left heart failure]. Rev Med Interne; 2005 Nov;26(11):874-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathophysiology and therapeutic implications of left heart failure].
  • [Transliterated title] Données physiopathologiques et implications thérapeutiques au cours de l'insuffisance cardiaque gauche.
  • PURPOSE: Heart failure is the ultimate step of most cardiovascular diseases.
  • The prognosis is very poor (5-year mortality: 50%) as is quality of life; heart failure is a very costly disease.
  • The treatment systematically combines: general advice, dietary measures; medical treatment (with betablockers, ACE inhibitors and/or angiotensin II receptor antagonists, diuretics, in some cases aspirin or oral anticoagulants, digitalis and amiodarone) according to severity of heart failure, presence of congestion, aetiology, age; etiologic treatment if possible; treatment and prevention of precipitating and exacerbating factors.
  • According to clinical and paraclinical features, one may propose cardiac multisite stimulation, cardiac surgery, physical stress training and cardiac transplantation.
  • In order to decrease frequency of heart failure, prevention of cardiovascular diseases which lead to heart failure must be done as often is possible (hypertension, valvular heart disease, ischemic heart disease).
  • FUTURE PROSPECTS AND PROJECTS: The future of the treatment of heart failure is the multidisciplinary management of heart failure (networks) led by hospital units specialized in heart failure.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271807.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Diuretics
  • [Number-of-references] 30
  •  go-up   go-down


98. Hiramitsu S, Miyagishima K, Kimura H, Mori K, Shiino K, Yamada A, Kato S, Kato Y, Morimoto S, Hishida H, Ozaki Y: Management of severe heart failure. Circ J; 2009 Jun;73 Suppl A:A36-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of severe heart failure.
  • Patients admitted to the hospital with heart failure (HF) include those with new-onset of acute HF and those with acute exacerbation of chronic HF (CHF).
  • Hitherto, CHF therapy was aimed at improving LV contractability, whereas more recently the aim has shifted to resting the heart.
  • When a HF patient fails to respond to all available therapies, heart transplantation becomes necessary.
  • Of the 1,000 HF patients admitted to our hospital, two cases received heart transplants.
  • 11 cases were indicated for heart transplantation but died before registration.
  • It should be remembered that although in Japan the possibility of receiving a heart transplant is very low, it is by no means entirely impossible.
  • [MeSH-major] Heart Failure / drug therapy. Heart Failure / surgery. Severity of Illness Index
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Diuretics / therapeutic use. Drug Therapy, Combination. Heart Transplantation. Humans

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474507.001).
  • [ISSN] 1347-4820
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Diuretics
  •  go-up   go-down


99. Carvalho VO, Pascoalino LN, Bocchi EA, Ferreira SA, Guimarães GV: Heart rate dynamics in heart transplantation patients during a treadmill cardiopulmonary exercise test: a pilot study. Cardiol J; 2009;16(3):254-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart rate dynamics in heart transplantation patients during a treadmill cardiopulmonary exercise test: a pilot study.
  • BACKGROUND: One way of defining an individual's heart effort is to calculate the maximum heart rate to be expected given their age, but the reinnervation seen in patients who have received heart transplants makes for different calculations from patients who have suffered heart failure.
  • The purpose of this study is to evaluate heart rate dynamics (rest, peak and percentage of predicted heart rate for age) in heart transplant patients compared to optimized beta-blocked heart failure patients during a treadmill cardiopulmonary exercise test.
  • METHODS: Twenty two (81% male, 46 +/- 12 years) sedentary heart failure patients and 15 (47% male, 44 +/- 13 years) sedentary heart transplant patients performed a treadmill cardiopulmonary exercise test between 10 am and 3 pm.
  • Heart failure optimization was considered 50 mg/day or more of carvedilol, with a resting heart rate of between 50 and 60 bpm.
  • RESULTS: Basal heart rate was lower in heart failure patients (58 +/- 5 bpm) compared to heart transplant patients (93 +/- 11 bpm; p < 0.0001).
  • Similarly, the peak heart rate (percentage of the maximum predicted for age) was lower in heart failure patients (60 +/- 13%) compared to heart transplant patients (80 +/- 12; p < 0.0001).
  • Maximum respiratory exchange ratio did not differ between the groups (1.05 +/- 0.06 in heart failure patients and 1.11 +/- 0.1 in heart transplant patients; p = 0.08).
  • Moreover, the heart rate reserve between heart failure (49 +/- 22) and heart transplantation (46 +/- 16%) was not different (p = 0.644).
  • CONCLUSIONS: No patient reached the maximum heart rate predicted for their age during a treadmill cardiopulmonary exercise test.
  • The heart rate reserve was similar between groups.
  • A heart rate increase in heart transplant patients during cardiopulmonary exercise test of more than 80% of the maximum age-adjusted value should be considered an effort near the maximum.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Carbazoles / therapeutic use. Exercise Test. Heart Failure / drug therapy. Heart Failure / surgery. Heart Rate / drug effects. Heart Transplantation. Propanolamines / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARVEDILOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437401.001).
  • [ISSN] 1897-5593
  • [Journal-full-title] Cardiology journal
  • [ISO-abbreviation] Cardiol J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Carbazoles; 0 / Propanolamines; 0K47UL67F2 / carvedilol
  •  go-up   go-down


100. Rabkin-Aikawa E, Mayer JE Jr, Schoen FJ: Heart valve regeneration. Adv Biochem Eng Biotechnol; 2005;94:141-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart valve regeneration.
  • The valves of the heart cannot regenerate spontaneously.
  • Therefore, heart valve disease generally necessitates surgical repair or replacement of the diseased tissue by mechanical or bioprosthetic valve substitutes in order to avoid potentially fatal cardiac or systemic consequences.
  • The innovative fabrication of materials and the development of sophisticated methods to repair or regenerate damaged or diseased heart valves requires integration of a diverse array of basic scientific principles and enabling technologies.
  • Thus, heart valve tissue engineering requires an understanding of relationships of structure to function in normal and pathological valves (including mechanisms of embryological development, tissue repair and functional biomechanics), and the ability to control cell and tissue responses to injury, physical stimuli and biomaterial surfaces, through chemical, pharmacological, mechanical and potentially genetic manipulations.
  • These approaches created by advances in cell biology raise exciting possibilities for in situ regeneration and repair of heart valves.
  • [MeSH-major] Heart Valves / physiology. Regeneration
  • [MeSH-minor] Bioprosthesis. Heart Valve Prosthesis. Humans. Tissue Engineering

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915872.001).
  • [ISSN] 0724-6145
  • [Journal-full-title] Advances in biochemical engineering/biotechnology
  • [ISO-abbreviation] Adv. Biochem. Eng. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 136
  •  go-up   go-down






Advertisement